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Under physiological conditions, adenosine triphosphate (ATP) is present at low levels in
the extracellular milieu, being massively released by stressed or dying cells. Once outside
the cells, ATP and related nucleotides/nucleoside generated by ectonucleotidases
mediate a high evolutionary conserved signaling system: the purinergic signaling, which
is involved in a variety of pathological conditions, including inflammatory diseases.
Extracellular ATP has been considered an endogenous adjuvant that can initiate
inflammation by acting as a danger signal through the activation of purinergic type
2 receptors—P2 receptors (P2Y G-protein coupled receptors and P2X ligand-gated
ion channels). Among the P2 receptors, the P2X7 receptor is the most extensively
studied from an immunological perspective, being involved in both innate and adaptive
immune responses. P2X7 receptor activation induces large-scale ATP release via its
intrinsic ability to form a membrane pore or in association with pannexin hemichannels,
boosting purinergic signaling. ATP acting via P2X7 receptor is the second signal to
the inflammasome activation, inducing both maturation and release of pro-inflammatory
cytokines, such as IL-1β and IL-18, and the production of reactive nitrogen and oxygen
species. Furthermore, the P2X7 receptor is involved in caspases activation, as well as
in apoptosis induction. During adaptive immune response, P2X7 receptor modulates
the balance between the generation of T helper type 17 (Th17) and T regulatory (Treg)
lymphocytes. Therefore, this receptor is involved in several inflammatory pathological
conditions. In infectious diseases and cancer, P2X7 receptor can have different and
contrasting effects, being an angel or a demon depending on its level of activation,
cell studied, type of pathogen, and severity of infection. In neuroinflammatory and
neurodegenerative diseases, P2X7 upregulation and function appears to contribute to
disease progression. In this review, we deeply discuss P2X7 receptor dual function and its
pharmacological modulation in the context of different pathologies, and we also highlight
the P2X7 receptor as a potential target to treat inflammatory related diseases.
Keywords: purinergic signaling, extracellular ATP, inflammation, macrophages, lymphocytes, neurodegenerative
diseases, inflammatory disease, sepsis
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INTRODUCTION
Adenosine triphosphate (ATP) has long been known as the
intracellular energy currency molecule of the cell. Under
physiological conditions, extracellular ATP (eATP) is present
at low levels (nanomolar range). However, this phosphate
compound can be released by stressed, injured, or dying cells,
reaching high concentrations (hundred micromolar) in the
extracellular milieu (Pellegatti et al., 2008; Wilhelm et al., 2010).
Once outside the cells, ATP and its metabolites (ADP, AMP, and
adenosine) generated by the action of ecto-enzymes—named
ectonucleotidases—mediate a high evolutionary conserved
signaling system: the Purinergic Signaling (Burnstock and
Verkhratsky, 2009; Verkhratsky and Burnstock, 2014).
Purinergic Signaling was first reported in the 1920s by Drury
and Szent-Gyorgyi, when the effects of adenine compounds
in the circulatory system of mammals were described (Drury
and Szent-Gyorgyi, 1929). In the 1950s, studies showed that
ATP was released from sensory nerves (Holton and Holton,
1954; Holton, 1959), but only in the 1970s, adenine compounds
were recognized as signaling molecules thanks to Geoffrey
Burnstock’s studies (Burnstock et al., 1970, 1972; Burnstock,
1972). Interestingly, the first article reporting the effects of
eATP in immune cells also dates back to the 1970s (Dahlquist
and Diamant, 1970). In their paper, Dahlquist and Diamant
(1970) described that eATP induces histamine release from mast
cells. Further studies involving these same cells have led to the
discovery of a specific receptor for eATP, later identified as the
P2X7 receptor subtype (Cockcroft and Gomperts, 1980). Since
then, especially in the last three decades, eATP-P2X7 receptor
signaling has become one of the most studied pathways in
infectious and inflammatory diseases.
P2X7 receptor is a ligand-gated ion channel belonging to
the purinergic type 2 receptor family (P2). P2 receptor family
comprises the P2Y G protein–coupled receptors (P2Y1,2,4,6,11−14)
and P2X receptors (P2X1–7), which are ligand-gated ion
channels (Ralevic and Burnstock, 1998; Abbracchio et al., 2006).
P2X7 is the most extensively studied receptor subtype from
an immunological perspective. Its sustained stimulation by
millimolar concentrations of eATP, triggers non-selective pore
formation, which allows the passage of molecules of up to 900
Da, Na+ and Ca2+ influx and K+ eﬄux resulting in changes in
the ionic homeostasis of the cell (Coutinho-Silva and Persechini,
1997). In addition, P2X7 receptor can initiate the release of large-
scale intracellular ATP via its intrinsic pore formation ability or
in association with pannexin hemichannels, therefore boosting
purinergic signaling and inflammation (Pelegrin and Surprenant,
2006).
Several other functions have been attributed to P2X7
receptor in innate and adaptive immune responses. It is widely
expressed by different immune cells including monocytes,
macrophages, neutrophils, lymphocytes, mast cells, among others
(reviewed in Lenertz et al., 2011; Jacob et al., 2013; Idzko
et al., 2014; Morandini et al., 2014b). During innate immune
response, damage-associated molecular patterns (DAMPs) or
pathogen-associated molecular pattern (PAMPs) activate pattern
recognition receptors (PRRs) (i.e., Toll-like receptors—TLRs)
inducing ATP release, which in turn can activate P2X7 receptor
(Cohen et al., 2013). In addition, TLR-mediated NF-κB pathway
activation act as the first signal promoting the transcription
of several genes encoding inflammatory mediators including
pro-IL-1β and inflammasome components, such as NLRP3 and
ASC. P2X7 receptor stimulation represents the second signal to
inflammasome activation by triggering K+ eﬄux, inflammasome
assembly, and subsequent caspase-1 activation. The later, in
turn, processes pro-IL-1β to its mature form which is able to
be released then (Ferrari et al., 1997, 2006; Qu et al., 2007;
Ting et al., 2008; Di Virgilio et al., 2017). P2X7 receptor also
promotes IL-6 release in a Ca2+-dependent mechanism (Shieh
et al., 2014). Moreover, P2X7 receptor stimulates the production
of free radicals (Cruz et al., 2007; Hewinson and Mackenzie,
2007; Hung et al., 2013) and it is involved in the activation
of caspases and phospholipases (Coutinho-Silva et al., 2003b;
Kahlenberg et al., 2005; Costa-Junior et al., 2011), as well as in
cell cycle regulation and apoptosis (Coutinho-Silva et al., 1999;
Bianco et al., 2006). P2X7 receptor also modulates intracellular
signaling pathways, such as MyD88/NF-κB, PI3K/Akt/mTOR,
and the activation of mitogen-activated protein kinase (MAPK)
pathway proteins (MEK, ERK 1/2) (Bradford and Soltoff, 2002;
Skaper et al., 2010; Liu et al., 2011; Bian et al., 2013; Savio et al.,
2017a).
During adaptive immune response, P2X7 receptor is directly
involved in T cell activation. Indeed, ATP-P2X7 receptor
signaling is required for TCR-mediated calcium influx and IL-2
production. The blockading of P2X7 receptor-mediated calcium
influx inhibited T cell activation (Yip et al., 2009). Moreover,
P2X7 receptor modulates the balance between the generation of
T helper type 17 (Th17) and T regulatory (Treg) lymphocytes
(Schenk et al., 2011; Cekic and Linden, 2016). ATP-P2X7 receptor
signaling decreases the suppressive activity and viability of Treg
cells and favors the polarization of T cells into Th17 cells (Schenk
et al., 2011). In addition, P2X7 receptor’s blockade facilitates the
conversion of naive CD4+ T cells into Treg cells (Schenk et al.,
2011).
Taking into account its crucial role in immune response,
it is expected that an imbalance in P2X7 receptor activation
may favor several pathological conditions including infectious,
inflammatory, and neurodegenerative diseases, as well as cancer.
Up until now, several studies have pointed different and
contrasting effects for P2X7 receptor, whose activation may
be able to either potentiate or ameliorate disease progression.
In this review, we discuss P2X7 receptor’s dual function and
its pharmacological modulation in the context of different
pathologies, as well as highlight its potential use as a therapeutic
target for the treatment of inflammatory related diseases.
P2X7 RECEPTOR AGONISTS,
ANTAGONISTS, AND KNOCKOUT
MICE—IMPORTANT CONSIDERATIONS
To date, no specific agonist for P2X7 receptor has been described
(De Marchi et al., 2016). The endogenous P2X7 receptor ligand,
eATP itself, has distinct effects on P2X7 activation depending
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on its concentration at the active site (Steinberg and Silverstein,
1987; Virginio et al., 1999; Hibell et al., 2000). As a rule, high
eATP concentrations (in the millimolar range—EC50≥ 100µM)
are required to activate P2X7 receptor (Surprenant et al., 1996;
Bianchi et al., 1999; Donnelly-Roberts et al., 2009). While high
micromolar levels of ATP stimulates P2X7 receptor to form
a cation-selective channel, prolonged exposure to millimolar
levels trigger a nonselective large cytolytic pore conformation,
allowing the passage of 900 Da molecules through the plasma
membrane (Steinberg and Silverstein, 1987; Virginio et al.,
1999; North, 2002). eATP is readily metabolized by extracellular
ectonucleotidases, dropping initially high eATP levels to much
lower levels (nanomolar to low micromolar), wherein it can
activate other P2X subtypes (De Marchi et al., 2016). In this
context, the non-hydrolyzable derivative ATP substrate, ATPγS,
is a better alternative for studies involving P2 receptor activation.
The benzoyl ester of ATP, BzATP, is far the most potent
P2X7 agonist available, being ∼10–30 times more potent than
ATP—with a low micromolar EC50 for the human receptor
(Surprenant et al., 1996; Bianchi et al., 1999). However, it can also
activate other P2X subtypes (such as P2X1 and P2X3) and it is
metabolized to other adenine derivatives (DeMarchi et al., 2016).
Besides lack of specificity, differences in agonist potency across
mammalian species are also an aggravating factor for studies
involving P2X7 receptor (Hibell et al., 2000).
Several molecules have been developed to block P2X7 receptor
activity (De Marchi et al., 2016). They can be subdivided
into orthosteric ligands—binding the receptor within the ATP-
binding cavity—and allosteric ligands—binding the receptor at
sites, other than the ATP-binding cavity, and decreasing the effect
of the endogenous ligand ATP (De Marchi et al., 2016). The
first group is represented by suramin or suramin-like derivatives,
ATP derivatives (TNP-ATP, periodate-oxidized ATP [oATP]),
tetrazole derivatives (A438079, A839977), and cyanoguanidine
derivatives (A740003, A804598) (De Marchi et al., 2016). Among
them, tetrazole and cyanoguanidine derivatives present the
highest potency and selectivity for P2X7 receptor vs. other P2X
and P2Y receptors (Honore et al., 2006; Nelson et al., 2006;
Carroll et al., 2007; Donnelly-Roberts et al., 2009; Adinolfi et al.,
2015; Amoroso et al., 2015). Their IC50 values vary according
to the compound and the mammalian species: A438079 IC50
is 0.13 and 0.32µM at the human and rat P2X7 receptors
(Nelson et al., 2006; Donnelly-Roberts et al., 2009), A839977
IC50 is 0.02–0.150µM at recombinant human, rat, and mouse
P2X7 receptors (Florjancic et al., 2008; Honore et al., 2009;
Friedle et al., 2010), A740003 IC50 is 0.040 and 0.020µM at
human and rat P2X7 receptor (Honore et al., 2006; Adinolfi
et al., 2015; Amoroso et al., 2015), and A804598 IC50 is 0.0109,
0.0099, and 0.0089µM at the human, rat, and mouse P2X7
receptors, respectively (Donnelly-Roberts et al., 2009). Unlike
the tetrazole and cyanoguanidine derivatives, ATP derivatives
(TNP-ATP and oATP) are potent P2X7 receptor antagonist
at high micromolar levels and can interact with other P2X
receptors (Di Virgilio, 2003; De Marchi et al., 2016). Moreover,
besides being an irreversible P2X7 antagonist (Easterbrook-
Smith et al., 1976), oATP itself appears to exert anti-inflammatory
effects, modulating the immune response independently of P2X7
blockage (Beigi et al., 2003; Di Virgilio, 2003; Figliuolo et al.,
2014). In this way, experiments using oATP to evaluate P2X7 role
in inflammatory diseases should be carefully analyzed.
The second group of P2X7 blocking molecules is represented
by a class of synthetic negative allosteric modulators such as
Brilliant Blue G (BBG), AZD9056, KN-62, AZ-11645373, AZ-
10606120, GW791343, GSK314181A, GSK1482160, CE-224,535,
AFC-5128, JNJ-479655, and EVT-401 (Guile et al., 2009; Friedle
et al., 2010; Kaczmarek-Hájek et al., 2012; Alves et al., 2013;
North and Jarvis, 2013; Mehta et al., 2014). Even though these
compounds present nanomolar/micromolar potency at the P2X7
receptor, they can still interact with other P2X receptors’ allosteric
binding sites. For example, BBG have been widely used as a
selective antagonist for P2X7 receptor, but it can also block P2X1,
P2X4, and sodium channels (Jiang et al., 2000; Seyffert et al.,
2004; Jo and Bean, 2011). Therefore, divergent and unexpected
results found in P2X7 receptor studies might be attributed to
different experimental settings where diverse agonist/antagonist
drugs with different affinity and specificity were used and hence
should be critically analyzed.
Regarding P2X7 receptor knockout (P2X7 KO) mice, at least
two strains are currently commercially available. One, generated
by GlaxoSmithKline, in which the lacZ gene and neomycin
cassette (Neo) were inserted into exon 1, and the second, from
Pfizer (commercially available from The Jackson Laboratory),
which has a Neo insertion in exon 13—exon coding for the long
C–terminal cytoplasmic tail (Sikora et al., 1999; Solle et al., 2001).
However, the identification of P2X7 splice variants revealed that
both knockout mice express P2X7 receptor on T cells, whereas
DCs,macrophages, and neurons do not (Taylor et al., 2009;Masin
et al., 2012). Although both P2X7 KOmice express P2X7 receptor
on T cells, only P2X7 KO mice from GlaxoSmithKline have a
functional P2X7 receptor in these cells (Taylor et al., 2009). T cells
obtained from Pfizer P2X7 KO mice did not respond to BzATP
stimulation, while lymphocytes from GlaxoSmithKline P2X7 KO
mice showed high levels of P2X7 activity in comparison to wild
type (WT) mice (Taylor et al., 2009).
Taken together, these reports indicate that studies using
GlaxoSmithKline KO mice for evaluating P2X7 receptor
relevance in an immunological context should be carefully
analyzed considering the tissue specific expression of a functional
P2X7 protein in T cells.
P2X7 RECEPTOR IN INFECTIOUS
DISEASES—ANGEL OR DEMON
DEPENDING ON THE TYPE OF
PATHOGEN, VIRULENCE, AND SEVERITY
OF INFECTION
In response to viral, bacterial, fungal, and protozoa infection,
ATP is released from immune and non-immune cells.
Subsequent activation of the ATP-gated P2X7 receptor has
been implicated in the pathophysiology of several infectious
diseases through modulation of innate and adaptive immune
responses (Coutinho-Silva and Ojcius, 2012; Morandini et al.,
2014b; Savio and Coutinho-Silva, 2016; Di Virgilio et al., 2017).
Interestingly, P2X7 receptor activation can generate both
beneficial and deleterious effects depending on the type of
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pathogen, virulence, and severity of infection (Figure 1). In the
next sections, both positive and negative effects of P2X7 receptor
activation are discussed. In addition, the effects of P2X7 receptor
pharmacological inhibition or genetic deletion in infectious
disease are summarized in Table 1.
P2X7 Receptor in Viral Infections
Host macrophages and L929 cells secrete ATP by exocytosis
and/or pannexin channels in response to viral infections (Zhang
et al., 2017). Extracellular ATP, acting via P2X7 receptor, regulates
immune responses against several types of viruses. ATP-P2X7
signaling decreases viral replication and consequently protects
bone marrow-derived macrophages (BMDM), macrophage cells
line RAW 264.7, and HEK 293T cells from cell death mediated by
vesicular stomatitis virus (VSV) infection in vitro. This happens
by inducing IFN-β secretion via activation of P38/JNK/ATF-2
signaling pathways (Zhang et al., 2017). In vivo, ATP treatment
reduces viral replication and improves survival of VSV-infected
FIGURE 1 | Schematic illustration showing P2X7 receptor protective (angel) and deleterious (demon) effects in immune responses against pathogens. The recognition
of pathogen-associated molecular pattern (PAMPs) by Pattern Recognition Receptors (PRRs) can induce ATP release, which activates P2X7 receptor. As a
consequence, P2X7 receptor activation induces ATP release—chiefly via pannexin hemichannels—boosting inflammation. (A) At a molecular level (upper panel) P2X7
receptor beneficial effects are mediated by the stimulation of microbicidal mechanisms and production of inflammatory mediators in phagocytic cells, such as ROS,
NO, and interleukins. P2X7 receptor acts as a second signal for NLRP3 inflammasome activation and IL-1β release. In addition, at a cellular level (low panel) P2X7
receptor is involved in the activation of effector T cells, and it favors the polarization of T cells into Th17 cells and decreases the suppressive activity and viability of
Tregs. (B) On the other hand, P2X7 can act as a demon depending on the type of pathogen, virulence, and severity of infection by inducing an excessive production
and release of inflammatory mediators (upper panel) coupled to a high incidence of apoptotic and necrotic cell death due the release of large amounts of ATP (low
panel), which results in sustained P2X7 receptor activation, leading to a self-sustained pro-inflammatory deleterious cycle.
Frontiers in Pharmacology | www.frontiersin.org 4 February 2018 | Volume 9 | Article 52
Savio et al. P2X7 Receptor: Angel or Demon?
TABLE 1 | Protective or deleterious effects of P2X7 receptor pharmacological inhibition or genetic deletion in infectious disease.
Pathogen or PAMP Pharmacological inhibitor or
genetic deletion
Effect Inflammatory mediator or immune cell
involved
References
VIRAL INFECTIONS
Vesicular stomatitis virus P2X7 KO mice Deleterious ↓IFN-β ↑viral replication Zhang et al., 2017
Adenoviral vectors oATP, A438079, P2X7 KO mice Protective ↓IL-1β, IL-6, NO, and neutrophil infiltration Lee et al., 2012
Influenza virus P2X7 KO mice Protective ↓INF-γ, TNF-α, IL-6, and neutrophil
infiltration
Leyva-Grado et al., 2017
HIV viral proteins in brain
cells
oATP, A438079, BBG, suramin Protective ↓ NF-κB activation, TNF-α, IL-1β, ROS,
NO, MCP-1, and neuronal damage
Tewari et al., 2015; Chen et al.,
2016
HIV PPADS, suramin Protective ↓ HIV-1 fusion CD4+ cells Swartz et al., 2014
HIV oATP, A740003, BBG, and
suramin
Protective ↓ HIV replication in macrophages Hazleton et al., 2012
BACTERIAL INFECTIONS
C. trachomatis P2X7 KO mice Deleterious ↓IL-1β ↑ bacterial burden Darville et al., 2007
P. gingivalis P2X7 KO mice Deleterious ↓IFN-γ, IL-17 Ramos-Junior et al., 2015
M. tuberculosis
• H37RV P2X7 KO mice Deleterious
↑ Treg
↑ bacterial burden
Santos et al., 2013
• Beijing 1471 or
MP287/03
P2X7 KO mice Protective
↓IL-1β and INF-γ
↓ bacterial burden
Amaral et al., 2014
M. bovis P2X7 KO mice Protective
↓immature-like myeloid cells
↓ bacterial burden
Bomfim et al., 2017
Sepsis
• Endotoxic shock (LPS) P2X7 KO mice Protective
↑ survival
↓cytotoxicity
Yang et al., 2015
• CLP model A438079, P2X7 KO mice Protective
↓IL-1β, CXCL1 and CX3CL1
↑ survival
Wang et al., 2015a
• CLP model A740003 Protective
↓ p-NF-κB, IL-1β, IL-6,
Wu et al., 2017a
• CLP model P2X7 KO mice, BBG Protective
↓p-NF-κB, IL-1β, IL-6, NO, ALT, and
neutrophil infiltration
↑ survival
Santana et al., 2015
Savio et al., 2017a
Savio et al., 2017b
• CLP model P2X7 KO mice, oATP Deleterious
↑ IL-1β, IL-6, TNF-α and bacterial burden
↓ survival
Csóka et al., 2015a
FUNGAL INFECTIONS
C. albicans KN-62 Deleterious
↓DC activation, PGE2
Xu et al., 2016
P. brasiliensis P2X7 KO mice Deleterious
↓Th17/Th1 response
↑ fungal burden
Feriotti et al., 2017
PROTOZOA INFECTIONS
L. amazonensis P2X7 KO mice, A740003 Deleterious
↓ IL-1β and LTB4
Chaves et al., 2014
L. amazonensis P2X7 KO mice Deleterious
↑IFN-γ
↓ IL-17, IL-12, and TGF-β
↑parasitic load
Figliuolo et al., 2017a
T. gondii P2X7 KO mice Deleterious
↓TNF-α ↓survival
Miller et al., 2011
T. gondii P2X7 KO mice Deleterious
↓IFN-γ, TNF-α, IL-6,CD4+ cells
↑parasitic load
Huang et al., 2017
(Continued)
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TABLE 1 | Continued
Pathogen or PAMP Pharmacological inhibitor or
genetic deletion
Effect Inflammatory mediator or immune cell
involved
References
T. gondii P2X7 KO mice Deleterious
↓ IL-1β, IL-12, TNF-α, and IFN-γ
↑parasitic load
Corrêa et al., 2017
T. gondii P2X7 KO mice Deleterious
↓ IL-1β and ROS
↑parasitic load
Moreira-Souza et al., 2017
T. cruzi P2X7 KO mice Deleterious
↑ mast cells
Meuser-Batista et al., 2011
P. chabaudi P2X7 KO mice Deleterious
↓Th1 response
Salles et al., 2017
E. histolytica oATP, KN-62 Deleterious
↓ IL-1β
Mortimer et al., 2015
HELMINTH INFECTIONS
H. polygyrus BBG Deleterious
↓Mast cell activation
↓IL-13
Shimokawa et al., 2017
S. mansoni P2X7 KO Deleterious
↑TGF-β1
↓ survival
Oliveira et al., 2014
WT mice. This antiviral effect is not observed in P2X7 KO mice
(Zhang et al., 2017). Additionally, activation of P2X7 receptor is
crucial to control infection of humanmonocytes by dengue virus-
2 (Corrêa et al., 2016). Those findings suggest an important role
for this receptor in restraining viral replication and infection. On
the other hand, P2X7 receptor activation boosts inflammation
and potentially contributes to an exacerbated immune response,
depending on the virulence and severity of the infection. In
this context, Lee et al. (2012) showed that genetic deletion or
pharmacological inhibition of P2X7 receptor improves survival
in a mouse model of acute respiratory distress syndrome induced
by intranasal administration of replication deficient adenoviral
vectors. Improved outcome observed in these settings correlated
with decreased production of inflammatory mediators (i.e., IL-1β
and IL-6) and reduced neutrophil infiltration (Lee et al., 2012).
Similar results were observed in P2X7 KO mice infected with a
lethal dose of influenza virus (Leyva-Grado et al., 2017).
A role for extracellular ATP and P2X7 receptor in human
immunodeficiency virus (HIV) infection has also been reported
(Barat et al., 2008; Swartz et al., 2014, 2015; Graziano et al., 2015).
Broad-spectrum P2 receptor antagonists, such as PPADS and
suramin, significantly inhibit HIV-1 membrane fusion in CD4+
cells (Swartz et al., 2014, 2015). In addition, P2X7 inhibitors
oATP, A740003, BBG, and suramin decrease HIV replication
in human macrophages (Hazleton et al., 2012). Graziano
et al. (2015) showed that ATP induces the release of HIV-1
virions derived from virus containing compartments (subcellular
vacuoles), present in monocyte-derived macrophages. P2X7
receptor blockade with A438079 prevented eATP-induced release
of virions from monocyte-derived macrophages and D-U1 cells,
a chronically HIV-1infected promonocytic cell line. Imipramine,
an inhibitor of ceramide formation, also blocked virions release
from these cells, suggesting that P2X7 activation stimulates
ceramide production, thus favoring the formation of exosomes
containing HIV-1 virions. Therefore, targeting P2X7 receptor
might be a suitable therapeutic strategy to eliminate HIV-1
reservoirs in individuals receiving combination antiretroviral
therapy (cART) (Graziano et al., 2015).
Evidence supporting the involvement of P2X7 receptor
in the deleterious effects caused by HIV-1 infection in the
central nervous system (CNS) has also been described (Swartz
et al., 2015). After primary infection, HIV virus invades the
CNS, resulting in neuroinflammation and neurodegeneration.
Viral proteins and inflammatory factors produced during the
immune response against HIV induce blood-brain barrier (BBB)
dysfunction and activate glial cells. BBB dysfunction facilitates
transmigration of infected monocytes and CD4+ T cells, further
propagating infection and inflammation within the CNS. The
HIV viral protein called transactivator of transcription (Tat) is
described as an important neurotoxin detected in the CNS of
HIV-1 infected subjects and it is responsible for triggering P2X7
receptor overexpression in human astrocytes and to promote
neuroinflammation (Tewari et al., 2015). Tat enhances the
expression of monocyte chemoattractant protein 1 (MCP-1) in
human astrocytes in a P2X7-dependent manner (Tewari et al.,
2015). In addition, the glycoprotein gp120 (gp120)—an HIV
envelope glycoprotein—increases P2X7 receptor expression in
BV2 microglia cells (Chen et al., 2016) and in hippocampus of
rats (Liu et al., 2017). Pretreatment with BBG has prevented NF-
κB activation and production of inflammatorymediators induced
by gp120 in BV2 cells (Chen et al., 2016), suggesting a key role
for P2X7 receptor in HIV-induced glial cells activation and brain
damage.
These findings support the contribution of P2X7 receptor
in viral infections promoting protective and deleterious effects
depending on viral strain and severity of the infection, which
makes the use of P2X7 receptor pharmacological blockers or
activators a challenging task on these settings.
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P2X7 Receptor in Bacterial Infections
In the 90’s, Humphreys and Dubyak (1996) published one of
the first reports describing the enhancement of P2X7 receptor-
mediated cell responses, such as membrane permeability and
Ca2+ influx, in response to lipopolysaccharide (LPS). Currently,
it is well-documented that TLRs activation by bacterial products,
such as LPS, induces ATP release from immune cells, modulating
inflammatory responses (Coutinho-Silva and Ojcius, 2012;
Cohen et al., 2013; Morandini et al., 2014b; Di Virgilio et al.,
2017). The role of P2X7 receptor in activation of microbicidal
mechanisms and production of inflammatory mediators in
phagocytic cells, as well as modulation of adaptive immune
responses to bacterial infection, have been extensively studied
(Coutinho-Silva and Ojcius, 2012; Morandini et al., 2014b; Di
Virgilio et al., 2017). In this section, we highlight the role of
this purinergic receptor in some important bacterial diseases,
including Chlamydia disease, Tuberculosis, Periodontitis, and in
bacterial Sepsis.
Chlamydiae Infections
Chlamydiae are obligatory intracellular pathogenic bacteria that
infect epithelial cells and macrophages. Chlamydiae can evade
host defense mechanisms mainly by inhibiting phagosome–
lysosome fusion and acidification (Herweg and Rudel, 2016;
Pettengill et al., 2016). Interestingly, ATP, acting through
P2X7 receptor, decreases bacterial load in macrophages and
epithelial cells infected with different Chlamydia species and
strains (Coutinho-Silva et al., 2001b, 2003b; Darville et al.,
2007) by overriding Chlamydiae’s evasion mechanisms. P2X7
receptor activation in Chlamydia-infected macrophages induces
phospholipase D activation, intracellular Ca+2 mobilization,
and subsequent phagolysosome formation and acidification
(Coutinho-Silva et al., 2003b). P2X7 genetic deletion increased
inflammation in the endocervix, oviduct, and mesosalpingeal
tissues in a model of Chlamydia vaginal infection, making P2X7
KO mice more susceptible to infection than wild-type mice
(Darville et al., 2007). In addition, P2X7 receptor is important
for NLRP3 inflammasome activation and IL-1β secretion, which
contributes to an efficient immune response against Chlamydiae
infections (Abdul-Sater et al., 2010; He et al., 2010; Shimada et al.,
2011; Nagarajan et al., 2012). Therefore, these reports suggest a
role for P2X7 receptor in the control of Chlamydiae infections by
increasing the microbicidal mechanisms in infected cells and the
immune response against these bacteria.
Porphyromonas gingivalis Infection
The importance of P2X7 receptor in the immune response
against bacteria involved in the pathogenesis of periodontitis,
such as Porphyromonas gingivalis, has been explored over the last
decade (reviewed in Almeida-da-Silva et al., 2016). P. gingivalis
is an intracellular bacteria member of the polymicrobial dental
biofilm community, which is involved in the pathogenesis
of periodontitis. P. gingivalis infection induces ATP secretion
from macrophage-derived THP-1 cells. Released ATP, in turn,
activates P2X7 receptor, which is crucial for K+ eﬄux and
NLRP3 inflammasome activation, inducing IL-1β secretion and
pyroptotic cell death (Park et al., 2014). P2X7/P2X4 receptors
are also required for ROS-mediated NLRP3 inflammasome
formation and IL-1β secretion in P. gingivalis-infected gingival
epithelial cells (Choi et al., 2013; Hung et al., 2013).
However, P. gingivalis has an ATP-consuming enzyme called
nucleoside diphosphate kinase (NDK), a strategy to subvert these
microbicidal mechanisms triggered by P2X7 receptor activation.
When secreted, NDK metabolizes eATP, inhibiting ATP/P2X7
receptor-mediated ROS production and apoptosis of gingival
epithelial cells (Yilmaz et al., 2008; Choi et al., 2013). Moreover,
P. gingivalis fimbriae impair P2X7-dependent IL-1β secretion in
murine macrophages (Morandini et al., 2014a).
Finally, Ramos-Junior et al. (2015) showed the importance
of this receptor for the adaptive immune response during
P. gingivalis infection by using P2X7 receptor deficient mice.
Draining lymph node cells from P2X7 KOmice produced less IL-
17 and IFN-γ compared to cells fromWT-infected mice (Ramos-
Junior et al., 2015). Therefore, P2X7 receptor seems to be a
potential target for the development of new strategies to treat
periodontitis. Additional detailed information regarding the role
of P2X7 receptor and inflammasomes in P. gingivalis can be
found in a recent review (Almeida-da-Silva et al., 2016).
Mycobacterial Infections
P2X7 receptor expression increases in peripheral blood
mononuclear cells from patients with tuberculosis (Franco-
Martínez et al., 2006). Also, P2X7 receptor’s loss-of-function
polymorphisms have been linked to an increased susceptibility
to pulmonary (Sharma et al., 2010; Areeshi et al., 2015; Wu et al.,
2015; Shamsi et al., 2016) and extra-pulmonary tuberculosis
(Fernando et al., 2007; Sharma et al., 2010; Ben-Selma et al., 2011;
Singla et al., 2012). This elevated susceptibility was correlated
with an impaired capacity of macrophages to eliminate the
bacillus (Fernando et al., 2007).
Molloy et al. (1994) showed for the first time that eATP is able
to induce mycobacterial killing in infected human monocytes.
Several subsequent studies described that eATP, acting via P2X7
receptor, induces mycobacterial killing in infected macrophages
by mechanisms which are dependent on phospholipase D
activation and apoptosis of infected cells (Kusner and Adams,
2000; Fairbairn et al., 2001; Placido et al., 2006). Interestingly,
in vivo studies have shown that the susceptibility of P2X7
KO mice to mycobacterium infection depends on the strains,
virulence and severity of the infection. Santos et al. (2013)
reported that P2X7 deficient mice were more susceptible to
mycobacterium infection when exposed to a high dose of the
common laboratory strain H37Rv. On the other hand, P2X7
KO mice infected with hypervirulent strains (Beijing1471 or
MP287/03) were less susceptible to infection than WT mice
(Amaral et al., 2014).
The reduced susceptibility of P2X7 KO mice is verified
because hypervirulent mycobacteria lead to macrophage death
by necrosis in a P2X7 receptor-dependent manner increasing
the bacillus release. So, the deleterious effects of P2X7 receptor
observed in hypervirulent mycobacteria infection may be related
to a vicious cycle where high eATP amounts are released by
damaged cells, exacerbating inflammation, lung damage, and
bacillus spreading (Amaral et al., 2014). Bomfim et al. (2017)
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recently showed that bone marrow-derived cells expressing
P2X7 receptor have a critical role in promoting progression of
severe tuberculosis. Therefore, P2X7 receptor is a key player in
the modulation of immune responses against mycobacterium
infections presenting protective or deleterious effects depending
on mycobacterial strains.
Bacterial Sepsis
Sepsis is the leading cause of death in intensive care units
worldwide and represents amajor public health issue. During this
life-threatening condition, the body’s unfettered inflammatory
response to a pathogen, commonly bacteria, triggers a cascade
of events, which culminate in death by multiple organ failure
(Singer, 2016). Plasma ATP levels increase in sepsis, suggesting
a possible role for this pro-inflammatory molecule in the
development of excessive systemic inflammation, characteristic
of the disease (Cauwels et al., 2014; Sumi et al., 2014).
The potential role of ATP and purinergic signaling in the
pathophysiology of sepsis has been explored in humans and
different animal models over the last few years (Haskó et al., 2011;
Vuaden et al., 2011; Cauwels et al., 2014; Sumi et al., 2014; Csóka
et al., 2015a,b; Ledderose et al., 2016; Savio et al., 2017a).
Two putative genotypes composed of five functional P2X7
receptor single nucleotide polymorphisms (SNPs) have been
identified in patients with sepsis (Geistlinger et al., 2012). In
the sequence, P2X7 functionality tests in dendritic cells isolated
from healthy individuals that carry the same SNPs previously
identified in septic patients were performed. These tests
revealed an improved P2X7 receptor functionality, characterizing
those as gain-of-function SNPs with deleterious effects in
sepsis (Geistlinger et al., 2012). Animal models support this
assumption by demonstrating that P2X7 receptor contributes
to the production of inflammatory cytokines and exacerbates
inflammatory response in sepsis (Santana et al., 2015;Wang et al.,
2015a; Yang et al., 2015; Savio et al., 2017a,b; Wu et al., 2017a).
P2X7 receptor genetic deletion improved survival rate by 30%
as compared to septic WT mice (Santana et al., 2015). Similarly,
Wang et al. (2015a) reported that A438079-treated WT mice or
P2X7 KO mice showed a significant reduction in the mortality
rate (50%) in a sepsis model of cecal ligation puncture (CLP)
surgery.
Moreover, systemic administration of BzATP increases
inflammation, while the systemic blockade of P2X7 receptor
with A740003 decreases levels of serum and intestinal mucosal
pro-inflammatory cytokines after CLP (Wu et al., 2017a).
The reduced inflammatory response in A740003-treated mice
protects them against sepsis-induced intestinal barrier disruption
(Wu et al., 2017a). BBG treatment has also been shown to
improve outcomes in sepsis. We recently showed that BBG
improves survival, reduces cytokine production, activation of
inflammatory signaling pathways, and liver injury in CLP-
induced sepsis (Savio et al., 2017a). Accordingly, BBG-treated
mice showed significantly lower production of inflammatory
mediators, such as IL-1β and TNF-α, as well as a tendency
toward better survival rate after intravenously administration of
a uropathogenic α-haemolysin producing E. coli strain (ARD6)
(Greve et al., 2017).
Other studies suggest that P2X7 receptor activation might
be protective in sepsis by enhancing macrophage’s ability to kill
bacteria, and increasing secretion of IgM by B1 cells lymphocytes
(Proietti et al., 2014; Csóka et al., 2015a). Intriguingly, Csóka
et al. (Csóka et al., 2015a) showed higher levels of inflammatory
chemokines and cytokines and increased mortality rate in P2X7
KO mice after sepsis by CLP compared to WT mice. Csóka
et al. (2015a) also demonstrated increased cytokine levels in
septic mice treated with oATP (an irreversible non-specific P2X7
antagonist), conflicting with several reports conferring anti-
inflammatory properties to oATP by inhibition of P2X7 receptor,
and other inflammatory signaling pathways (i.e., MyD88/NF-kB)
and cytokine production in vitro and in models of autoimmune
disease (Beigi et al., 2003; Vergani et al., 2013a,b; Savio et al.,
2017a).
As in Csòka’s findings, Greve et al. (2017) also showed
increased susceptibility of P2X7 KOmice from GlaxoSmithKline
(Brentford, UK)—mice that express a functional P2X7 protein
in T cells—to a severe model of sepsis, in which mice received
a high dose (165 million) of ARD6 E. coli strain intravenously.
However, no significant differences were observed in bacterial
load and plasma TNF-α, keratinocyte chemoattractant (KC), IL-
1β and IL-6 between P2X7 KO andWTmice, 2.5 h after injection
of a high dose of ARD6. Surprisingly, increased levels of IL-1β
and IL-6, but not KC and TNF-α were reported in P2X7 KO
mice injected with a low dose (41 million) of ARD6. The authors
propose that the higher production of IL-1β in P2X7 KO receptor
mice occurs via a non-canonical caspase8-dependent mechanism
(Greve et al., 2017).
Finally, opposing results regarding the P2X7 receptor in sepsis
could be related to differences in the mice microbiome, bacterial
virulence, and severity of the infection. Although the P2X7
receptor may be relevant to bacterial control, morbidity, and
mortality in this complex disease are related to onset of shock and
hemodynamic compromise with multiple organ dysfunction and
failure due to the excessive, unfettered inflammation in response
to a pathogen. Since studies in humans and animal models
have shown that P2X7 receptor contributes to the exacerbated
inflammatory response, the use of P2X7 receptor inhibitors in
addition to the antibiotic therapy seems to be a promising
therapeutic strategy for sepsis management.
P2X7 Receptor in Fungal Infections
A limited number of studies have explored the role of P2X7
receptor in fungal infections. Perez-Flores et al. (2016) reported
that P2X7 receptor in J774 cells functions as a scavenger receptor
for bacteria but not yeast. P2X7 receptor is not required for
NLRP3 activation and IL-1β secretion during Candida albicans
infection, an opportunistic fungal pathogen. In vitro, P2X7 KO
andWTmacrophages secreted similar levels of IL-1β in response
to C. albicans infection (Hise et al., 2009).
On the other hand, Xu et al. (2016) showed that invariant
natural killer T (iNKT) cells interact with DC and release ATP,
which activates P2X7 receptor in DC. P2X7 receptor activation
in DC induces secretion of prostaglandin E2 (PGE2) stimulating
neutrophil recruitment and controlling C. albicans infection.
P2X7 deficient mice were more susceptible to pulmonary
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paracoccidioidomycosis, a disease caused by the dimorphic
fungus Paracoccidioides brasiliensis (Feriotti et al., 2017). P2X7
receptor is crucial for the induction of an efficient Th1/Th17
immune response against P. brasiliensis in an NLRP3-dependent
manner (Feriotti et al., 2017). Although P2X7 receptor may
contribute to immune responses against certain fungal infections,
further studies evaluating the relevance of pharmacological
manipulation of P2X7 receptor in this field are necessary.
P2X7 Receptor in Protozoa Infections
Over the last decade, our laboratory has been exploring the role
of P2X7 receptor in Leishmaniasis, a neglected tropical disease
caused by a parasite of the genus Leishmania (Alvar et al.,
2012). P2X7 receptor expression is upregulated in Leishmania
amazonensis-infected macrophages and its activation reduces
parasitic load in these cells (Chaves et al., 2009). Mechanistically,
we demonstrated that activation of P2X7 receptor in infected
macrophages reduces parasitic load via leukotriene B4 (LTB4)
production (Chaves et al., 2009, 2014). Moreover, macrophage
infection with L. amazonensis induced P2X7 receptor-mediated
membrane permeabilization to anionic dye molecules, while it
strongly decreased the uptake of cationic dyes (Marques-da-Silva
et al., 2011). Interestingly, oATP affects parasite integrity and
macrophage function by inhibiting the attachment/entrance of
L. amazonensis promastigotes in a P2X7 receptor-independent
manner (Figliuolo et al., 2014).
Recently, we showed that P2X7 receptor modulates the
balance between inflammation and parasite control through a
series of in vivo experiments where we infect P2X7 KO and WT
mice with L. amazonensis. In a mousemodel where subcutaneous
L. amazonensis infection is induced by subcutaneous injection
of the parasite in the footpad, genetic deletion of P2X7 receptor
resulted in increased cell infiltration, higher IFN-γ levels, and low
concentrations of IL-17 and TGF-β in the footpad, suggesting
an excessive pro-inflammatory response. In addition to that,
CD4+ and CD8+ T cells from infected P2X7 KO mice exhibited
higher proliferative capacity than cells from infected WT mice
(Figliuolo et al., 2017a). P2X7 KO mice were more susceptible
to L. amazonensis infection showing increased lesion size and
parasitic load (Figliuolo et al., 2017a). Increased susceptibility
of P2X7 KO mice to L. amazonensis might be related to the
role of P2X7 receptor in controlling T cell proliferation by
inducing apoptosis. P2X7 KO mice showed an excessive CD4+
T cell proliferation which has a pathogenic role in leishmaniasis
(Figliuolo et al., 2017a). Thus, P2X7 receptor is crucial for the
immune response during leishmaniasis by regulating both innate
and adaptive immunity.
P2X7 receptor also plays a key role in the microbicidal
mechanisms that control infection by Toxoplasma gondii, a
protozoan parasite that infects most species of warm-blooded
animals causing toxoplasmosis. P2X7 receptor activation
in T. gondii infected macrophages mediates pathogen
elimination through ROS production and acidification of
the parasitophorous vacuole (Corrêa et al., 2010; Lees et al.,
2010). Mechanistically, we recently showed that P2X7 receptor
controls T. gondii infection via ROS generated from NADPH
oxidase, while IL-1β stimulates mitochondrial ROS production
(Moreira-Souza et al., 2017). In intestinal epithelial cells, P2X7
receptor induces production of cytokines and chemokines
that contribute to host immune response against T. gondii
infection (Huang et al., 2017). P2X7 KO mice showed increased
susceptibility to toxoplasmosis characterized by an impaired
production of pro-inflammatory cytokines (IL-1β, IL-12, TNF-α,
and IFN-γ) and increased tissue damage and parasitic load
(Miller et al., 2011, 2015; Corrêa et al., 2017; Huang et al., 2017).
Accordingly, loss-of-function SNPs in the human P2X7 receptor
gene have been directly associated with increased susceptibility to
toxoplasmosis by generating less functional proteins (Jamieson
et al., 2010). Therefore, P2X7 receptor functionality is crucial to
mount an efficient immune response against T. gondii infection.
P2X7 receptor relevance in the pathophysiology of Chagas
disease or American trypanosomiasis, a tropical disease caused
by the parasite Trypanosoma cruzi, has also been explored.
By mechanisms still unknown, this parasite potentiates P2X7
receptor sensitivity to ATP, increasing plasma membrane
permeabilization, calcium signaling, and death of CD4+/CD8+
double positive thymocytes during the atrophy phase of disease in
a murine model (Mantuano-Barradas et al., 2003). Nevertheless,
experiments performed with P2X7 KO mice suggested that this
receptor might not be critically involved in T. cruzi-mediated
thymus atrophy (Cascabulho et al., 2008). On the other hand,
P2X7 KO mice showed an increased migration of mast cells
toward the inflamed heart, which may compromise the innate
immune response against T. cruzi (Meuser-Batista et al., 2011).
Importantly, P2X7 receptor expression and functionality is not
altered in peripheral lymphocytes from patients with Chagas
Disease (Souza et al., 2017).
The role of P2X7 receptor in Malaria, a blood disease caused
by the plasmodium parasite transmitted by the Anopheles
mosquito, has also been explored since plasmodium-infected
erythrocytes release large amounts of ATP (Akkaya et al.,
2009). Extracellular ATP increases Ca2+ levels in P. falciparum
modulating parasite invasion. Interestingly, treatment with pam
P2 inhibitor suramin or apyrase before infection significantly
reduces invasion of red blood cells by P. falciparum (Levano-
Garcia et al., 2010). Recently, we have shown that ATP released
by rupture of infected erythrocytes activates P2X7 receptor in
CD4+ T inducing a Th1 immune response during blood-stage
Plasmodium chabaudimalaria. P2X7 receptor deficientmice were
more susceptible to plasmodium infection due to an impaired
Th1 immune response (Salles et al., 2017). Therefore, P2X7
receptor is important for the development of an efficient immune
response against plasmodium infection.
Finally, Mortimer et al. (2015) described that infection
by Entamoeba histolytica, an extracellular human parasite
that causes intestinal and extra-intestinal amebiasis, induces
α5β1 integrin activation and ATP release through pannexin-1
channels activating P2X7 receptor and, consequently, NLRP3
inflammasome in macrophages. These results highlight the role
of ATP-P2X7-NLRP3 inflammasome axis in the inflammatory
immune response during amebiasis.
Overall, these data support a role for ATP-P2X7 receptor
in boosting the immune system against the protozoa
infections. Nevertheless, peculiarities of each parasite infection
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should be considered when developing pharmacological
treatments targeting P2X7 receptor during protozoan
infections.
P2X7 Receptor in Helminth Infections
Helminths are worm-like parasites that currently infect more
than 1 billion people worldwide (Hotez et al., 2014). These
worms usually induce a type 2 immune response, increasing
susceptibility to infections by other lethal pathogen, being a
serious socioeconomic problem in developing countries (Cortés
et al., 2017).
P2X7 receptor has been implicated in the immune response
against helminth parasites. Recently, Shimokawa et al. (2017)
showed that P2X7 receptor activated by ATP released from
intestinal epithelial cells induces the production of IL-33 by mast
cells, which is crucial for induction of IL-13-producing group
2 innate lymphoid cells and clearance of helminth infections.
In addition, soluble products derived from Trichuris suis (a
type of helminth) downregulated P2X7 receptor expression in
DC and macrophages. Co-stimulation of DC and macrophages
with LPS and T. suis soluble products caused lower levels of
IL-1β compared to LPS-primed cells, indicating a reduction
in the activation state and inflammatory response of human
macrophages (Ottow et al., 2014).
Purinergic signaling is also altered during Schistosomiasis,
a chronic inflammatory disease caused by blood fluke worms
belonging to the genus Schistosoma (Oliveira et al., 2013, 2014,
2016; Silva, 2016). P2X7 receptor functionality, as assessed
by ATP-mediated Ca2+ influx and cell permeabilization,
is reduced in mesenteric endothelial cells (Oliveira et al.,
2013) and peritoneal macrophages from S. mansoni
infected mice. This reduction is caused by increased TGF-
β1 levels, which can reduce P2X7 receptor cell surface
expression (Oliveira et al., 2014). Moreover, P2X7 KO mice
infected with S. mansoni died 60 days after the infection,
while no death was observed in S. mansoni-infected WT
mice (Oliveira et al., 2014), suggesting that this receptor
is crucial for an efficient immune response against this
worm.
Taken together, these reports showed that helminth infections
downregulate P2X7 functionality and expression. Since this
receptor is crucial for controlling these infections, the use of P2X7
agonists could be a therapeutic strategy to boost the immune
response against these worms.
P2X7 RECEPTOR IN INFLAMMATORY
DISEASE—A DEMON VIA EXACERBATION
OF THE INFLAMMATORY STATE
P2X7 receptor is involved in several physiological and
pathological conditions in different body systems by modulating
cellular responses in immune and non-immune cells in a variety
of disease (Burnstock, 2017b). In this section, we discuss the
role of P2X7 receptor in inflammatory disease, including the
respiratory tract, gut, liver, and renal diseases as well as in
diabetes.
P2X7 Receptor in Respiratory Tract
Diseases
Purinergic signaling modulates important physiological
processes in the airways. P2 purinergic receptors are expressed
in different cells present in the respiratory system, such as
type I alveolar epithelial cells, pulmonary endothelial cells,
and resident immune cells (Mishra et al., 2011; Burnstock
et al., 2012). Mishra et al. (2011) reported that P2X7 receptor
activation with BzATP increases surfactant secretion in
primary cultures of alveolar epithelial cells. However,
this effect was blocked by BBG treatment. In addition,
P2X7 KO mice showed impaired surfactant secretion in
response to hyperventilation, highlighting the physiological
importance of this receptor in lung homeostasis (Mishra et al.,
2011).
However, P2X7 receptor hyperactivation has been implicated
in the pathogenesis of a variety of respiratory diseases,
including pulmonary hypertension, asthma, chronic obstructive
pulmonary disease, acute lung injury, and pulmonary fibrosis
(reviewed in Burnstock et al., 2012; Gentile et al., 2015). Increased
ATP concentrations were detected in bronchoalveolar fluid of
patients with idiopathic pulmonary fibrosis as well as in the
bronchoalveolar space of mice subjected to a model of lung
inflammation induced by LPS (Riteau et al., 2010) or cigarette
smoking (Baxter et al., 2014).
Once released in the extracellular medium during lung
injury, eATP acts as a danger signal through activation of
P2X7 receptor, inducing alveolar macrophage activation and
secretion of IL-1β (Riteau et al., 2010; Wang et al., 2015b;
Galam et al., 2016) and IL-1α (Dagvadorj et al., 2015), and
neutrophil recruitment (Riteau et al., 2010; Monção-Ribeiro
et al., 2011; Baxter et al., 2014; Dagvadorj et al., 2015; Wang
et al., 2015b; Mishra et al., 2016). The activation of P2X7 receptor
increases markers of tissue fibrosis, such as lung collagen content
and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1)
during lung injury (Riteau et al., 2010; Monção-Ribeiro et al.,
2011). All these deleterious effects were attenuated in P2X7
KO mice (Riteau et al., 2010; Monção-Ribeiro et al., 2011;
Baxter et al., 2014; Dagvadorj et al., 2015; Galam et al.,
2016) or pharmacological inhibition of P2X7 receptor with
A438079 (Wang et al., 2015b), BBG (Wang et al., 2015b), and
suramin, a broad spectrum P2 receptor antagonist (Riteau et al.,
2010).
Experiments performed in vitro co-cultures of human
lung epithelial and macrophage cell lines suggest that P2X7
receptor also participates in lung inflammation triggered
by nanoparticles such as SiO2 and TiO2, through the
induction of inflammasome activation and IL-1β secretion
(Dekali et al., 2013). Moreover, Monção-Ribeiro et al. (2014)
showed that P2X7 receptor activation contributes to silica-
induced lung fibrosis. P2X7 receptor deficient or BBG-treated
mice showed diminished lung inflammation and fibrosis, as
well as improved pulmonary function after silica instillation
(Monção-Ribeiro et al., 2014). Therefore, P2X7 receptor
contributes to lung inflammation and fibrosis, being an
attractive therapeutic target to treat diseases of the respiratory
tract.
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P2X7 Receptor in Gut Disease
Several reports have described the participation of purinergic
signaling in pathophysiological mechanism of gut diseases
(reviewed in Burnstock, 2016; Longhi et al., 2017). P2X7 receptor
expression and functionality have been characterized in different
gut compartments (de Campos et al., 2012), and shown to be
upregulated in colon of patients with Crohn’s disease (CD)
(Neves et al., 2014).
Rodent animal models of inflammatory bowel disease have
shown that activation of P2X7 receptor induces death of enteric
neurons and intestinal inflammation by activation of mast cells in
the gut, leading to intestinal motility disorders (Gulbransen et al.,
2012; Kurashima et al., 2012; Antonioli et al., 2014; Matsukawa
et al., 2016). In this context, pharmacological inhibition of P2X7
receptor by BBG (Marques et al., 2014), A438079 (Wan et al.,
2016), and A740003 (Marques et al., 2014; Figliuolo et al.,
2017b) in animal models of inflammatory bowel disease showed
beneficial effects attenuating the inflammatory response in the
colon. Likewise, genetic deletion of P2X7 receptor protects mice
against chemically induced colitis (Neves et al., 2014; Figliuolo
et al., 2017b). Mechanistically, we recently demonstrated that
eATP, released from damaged cells or pathogenic bacteria,
contributes to chemically-induced colitis by triggering P2X7
receptor-mediated Treg cell death (Figliuolo et al., 2017b).
P2X7 receptor deletion increases the expression of CD103, an
integrin involved in T lymphocytes addressing the intestinal
epithelium, in mesenteric lymph nodes of mice with 2,4,6-
Trinitrobenzenesulfonic acid solution (TNBS)-induced colitis. In
this model, Treg cells leave the mesenteric lymph nodes and
migrate to lamina propria in greater numbers in P2X7 receptor
KO than WT mice. Increased number of activated Treg cells,
leading to higher levels of anti-inflammatory cytokines, such as
IL 10 and TGF-β, in the lamina propria of P2X7 receptor KO
mice protects them against experimental colitis (Figliuolo et al.,
2017b).
In contrast, studies reported by Hashimoto-Hill et al. (2017),
using a different model of colitis induced by Citrobacter
rodentium infection, suggest a protective role for upregulation
of P2X7 receptor expression in the gut. In their studies, retinoic
acid-induced P2X7 receptor expression in CD4+ effector T cells
in the intestine, by activation of the intragenic enhancer region of
the P2X7 receptor mouse gene, inhibited excessive expansion of
Th1 and Th17 cells in the intestine during colitis (Hashimoto-Hill
et al., 2017).
Taken together, these reports support the involvement of P2X7
receptor in inflammatory mechanisms underlying inflammatory
bowel diseases. Interestingly, a clinical trial evaluating the effects
of a selective orally active inhibitor of the P2X7 receptor
(AZD9056) showed beneficial effects in patients with moderate-
to-severe Crohn’s Disease (Eser et al., 2015). Therefore, this
receptor seems to be a suitable therapeutic target to treat gut
disease.
P2X7 Receptor in Liver Disease
Purinergic signaling has been implicated in liver inflammation
(Vaughn et al., 2012). Particularly, the P2X7 receptor is
involved in oxidative and inflammatory mechanisms, as well as
fibrogenesis, by inducing activation of Kupffer cells and hepatic
stellate cells in several liver diseases (Vaughn et al., 2012). P2X7
receptor blockade with A438079 attenuates mouse CCl4-induced
liver fibrosis (Huang et al., 2014). BBG or oATP treatment also
reduces the production of inflammatory mediators, activation of
inflammatory signaling pathways and liver fibrosis in a model of
bile duct ligation-induced cirrhosis (Tung et al., 2015).
Savio et al. (2017a) reported that P2X7 receptor blockade
with BBG protects mice against sepsis-induced liver injury by
decreasing activation of inflammatory signaling pathways,
cytokine production, and apoptosis of sinusoidal cells.
Pretreatment with BBG, followed by administration of
celastrol, a pentacyclic triterpene isolated from plants with
anti-inflammatory activity, also protects the liver from
acetaminophen-induced liver injury by reducing inflammation
and oxidative damage (Abdelaziz et al., 2017). In a model of
carbon tetrachloride-induced steatohepatitis in obese mice, P2X7
receptor mediates oxidative and inflammatory events in the liver
by NADPH oxidase-dependent mechanisms. P2X7 receptor
is required for NADPH oxidase activation by inducing the
expression of the p47 phox subunit and p47 phox binding to the
membrane subunit, gp91 phox, suggesting that P2X7 receptor
is involved in oxidative damage in liver disease (Chatterjee
et al., 2012). According to Das et al. (2013) this receptor is also
crucial for oxidative stress-mediated autophagy, inflammation,
and fibrosis in liver during experimental non-alcoholic
steatohepatitis in P2X7 KO mice (Das et al., 2013).
P2X7 receptor also contributes to acetaminophen
hepatotoxicity in mice (Hoque et al., 2012) and to hepatic
stellate cell activation and liver fibrogenesis via NLRP3
inflammasome and PKC/GSK3β pathways (Jiang et al., 2017; Wu
et al., 2017b). P2X7 receptor stimulation by BzATP induced the
expression of inflammatory mediators and proteins related to
fibrosis development, such as collagen I, in hepatic stellate cells
treated with acetaldehyde. These effects were attenuated by P2X7
receptor inhibition with A438079 (Wu et al., 2017b). Therefore,
P2X7 receptor blockade might be an innovative therapeutic
avenue to limit the activation of Kupffer and hepatic stellate cells,
and, consequently, the inflammation and fibrogenesis in liver
diseases.
P2X7 Receptor in Diabetes
Purinergic signaling has been studied in pancreas physiology and
pathophysiology since the 1960’s, when Rodrigue-Candela et al.
(1963) showed that ATP induces secretion of insulin in rabbit
pancreas slices. Currently, the role of several purinergic receptors
and ectonucleotidases in pancreas physiology and diabetes is
widely accepted (Burnstock and Novak, 2012, 2013). Specifically,
P2X7 receptor has been implicated in diabetes development
and pathology (Coutinho-Silva et al., 2007; Burnstock and
Novak, 2013). Polymorphisms in P2X7 receptor gene have been
associated with altered glucose homeostasis in both mice and
humans (Todd et al., 2015). In rat and mice, P2X7 receptor is
expressed in α cells, but not in β or δ cells, an expression pattern
that remains unchanged during aging or after streptozotocin
(STZ) administration (Coutinho-Silva et al., 2001a, 2003a).
Besides that, P2X7 receptor-mediated apoptosis is increased in
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fibroblasts from type 2 diabetes patients (Solini et al., 2004)
and in human fibroblasts exposed to high glucose levels (Solini
et al., 2000). In addition, osteoblast function is impaired in
a P2X7-dependent manner after high glucose exposure (Seref-
Ferlengez et al., 2016). Interestingly, Weitz et al. (2017) recently
showed that high glucose levels also induce ATP secretion
from β cells triggering the activation of pancreatic islet-resident
macrophages.
Using P2X7 receptor deficient mice, Glas et al. (2009) reported
that these mice subjected to a high-fat/high-sucrose diet have
diminished insulin secretion and glucose tolerance correlated
with an elevated number of apoptotic β cells. However, Chen
et al. (2011) reported that P2X7 genetic deletion did not alter
type 1 diabetes development in non-obese mice, while Vieira
et al. (2016) showed that P2X7 KO mice are resistant to STZ-
induced type 1 diabetes induction. No increase in blood glucose
and a decrease in insulin-positive cells were reported in STZ-
treated P2X7 KO mice in comparison to WT counterparts and
an analysis of pancreatic lymph nodes showed a diminished
inflammatory response in diabetic P2X7 KO mice. Finally, BBG
treatment also prevented the STZ-induced diabetes (Vieira et al.,
2016). Therefore, P2X7 receptor seems to be implicated in
diabetes types 1 and 2.
P2X7 receptor also appears to be involved in diabetes-
related comorbidities, including cardiovascular alterations,
diabetic retinopathy, and kidney injury (Burnstock and Novak,
2013). P2X7 receptor expression is increased in renal biopsy
sections from diabetic patients (Rodrigues et al., 2014; Menzies
et al., 2017a) and in the kidney of STZ-induced diabetic
rats contributing to diabetic nephropathy pathogenesis. P2X7
receptor blockade with AZ11657312 (Menzies et al., 2017a),
aerobic training or N-acetylcysteine administration attenuated
diabetes related kidney injury (Rodrigues et al., 2014). Therefore,
these results suggest that P2X7 receptor is involved in the
development of diabetes and associated comorbidities.
P2X7 Receptor in Kidney Disease
Purinergic signaling exerts crucial physiological effects on
renal function, controlling both vascular contractility and
tubular function (recently reviewed in Menzies et al., 2017b).
eATP released by renal cells regulates renal homeostasis
through activation of P2 purinergic receptors present in non-
hematopoietic renal cells as well as infiltrating immune cells
(Koo et al., 2017; Menzies et al., 2017b). Thus, an imbalance on
purinergic receptors activation, as well as in ectonucleotidases
activity, contributes to kidney diseases (Vuaden et al., 2012;
Franco et al., 2015).
Uncontrolled activation of P2X receptors, mainly P2X7
receptor, has been shown to play a critical role in the
inflammatory reactions observed in renal diseases, contributing
to renal glomerular, tubular, and vascular damage (Gonçalves
et al., 2006; Deplano et al., 2013; Solini et al., 2013; Franco
et al., 2015). This assumption is supported by the fact that, in a
healthy kidney, P2X7 receptor is weakly expressed in podocytes,
endothelial cells, mesanglial cells, and tubular epithelial cells,
while its levels become upregulated after injury (Gonçalves et al.,
2006; Solini et al., 2013; Burnstock et al., 2014; Rodrigues et al.,
2014; Franco et al., 2015).
In the same way, infiltrated inflammatory cells such
as macrophages, DCs, and T cells increase their P2X7
receptor expression after renal damage (Ji et al., 2012a,b;
Deplano et al., 2013; Koo et al., 2017). It is now clear that
activation of P2X7 receptor promotes pathologic inflammation
in several experimental models of renal diseases, such as
glomerulonephritis (Deplano et al., 2013), diabetic nephropathy
(Solini et al., 2013; Rodrigues et al., 2014), tubulointerstitial
nephritis (Gonçalves et al., 2006), hypertensive nephropathy
(Franco et al., 2015), acute kidney injury (Koo et al.,
2017), and chronic kidney injury (Granata et al., 2015) via
activation of NLPR3 inflammasome and consequent release of
inflammatory cytokine, such as IL-1β and IL-18. Moreover, this
receptor participates in the production of interstitial collagen,
contributing to renal fibrosis (Gonçalves et al., 2006; Koo et al.,
2017). Therefore, blocking P2X7 receptor activation may be a
potential strategy to prevent or ameliorate renal damage. In
fact, several studies have demonstrated a protective effect of
P2X7 receptor antagonism (with BBG, oATP, AZ10606120, A-
438079, and AZ11657312) or its genetic deletion in animal
models of renal injury due, primarily, to anti-inflammatory
actions (Gonçalves et al., 2006; Ji et al., 2012a,b; Deplano et al.,
2013; Solini et al., 2013; Menzies et al., 2015; Yan et al., 2015; Koo
et al., 2017).
In this sense, P2X7 receptor appears to be an attractive
therapeutic target to reduce inflammation in renal diseases.
Unfortunately, recent clinical trials failed to demonstrate a
beneficial effect for P2X7 receptor antagonists in several
inflammatory illnesses (Arulkumaran et al., 2011; Menzies et al.,
2017b). Additional detailed information regarding P2X7 receptor
role in renal disease and its potential use as a new target in renal
disease therapy can be found in a recent review (Menzies et al.,
2017b).
P2X7 Receptor in Cardiovascular Disease
Purinergic signaling and P2X7 receptor also play a key role
in cardiovascular physiology and pathophysiology. P2X7
receptor shows deleterious effects in cardiovascular disease
by promoting inflammation, thrombosis, and endothelial
dysfunction (Burnstock, 2017a). Additional detailed information
can be accessed in an excellent recent review by Burnstock
(2017a).
P2X7 RECEPTOR IN CANCER—ANGEL OR
DEMON DEPENDING ON ITS LEVEL OF
ACTIVATION AND CELL TYPE STUDIED
Despite recent advances in research and care, cancer is still a
major public health problem worldwide and it is the second
leading cause of death in the United States (Siegel et al., 2017).
Recent research has granted both pro- and anti-carcinogenic
properties to eATP in tumor biology. The definitive effect of
eATP will depend on its concentration in the tumor intersticium,
the panel of P2 receptor subtypes expressed by the tumor
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core and the levels of the ectonucleotidades expressed by
immune, tumor, and stromal cells (Di Virgilio, 2012). Increased
metabolism of eATP by CD39 and CD73 sequential enzymatic
activity generates adenosine in the tumor microenvironment
(TME), which is a potent immunosuppressive mediator and
promotes cancer cell growth (Ohta et al., 2006; Deaglio et al.,
2007; Mello et al., 2017b).
Particularly, P2X7 receptor activation has been linked to
conflicting effects on carcinogenesis, being beneficial in certain
circumstances and injurious in others (Roger et al., 2015).
In order to facilitate the understanding of P2X7 receptor
role in tumor progression, we will divide this following
sections according to its effect on tumor cells (pro-tumoral
and anti-tumoral) and immune infiltrated cells, highlighting
P2X7 receptor impact on the tumor-host interaction and its
inhibition/activation as a new therapeutic target potential in
cancer.
P2X7 Receptor Basal Stimulation in Tumor
Cells—Pro-tumoral Activities
Growing body of evidence indicates that P2X7 receptor plays
a central role in tumorigenesis (Adinolfi et al., 2009, 2012;
Tafani et al., 2011; Amoroso et al., 2015). P2X7 inhibition,
either by silencing or pharmacological blockade, restrained
tumor progression, and metastasis while P2X7 overexpression
accelerated it (Jelassi et al., 2011; Adinolfi et al., 2012).
Moreover, high expression levels of P2X7 receptor have
been found in many malignant human tumors, including
leukemia (Adinolfi et al., 2002; Zhang et al., 2004; Chong
et al., 2010), melanoma (Deli et al., 2007), neuroblastoma
(Raffaghello et al., 2006), pancreatic adenocarcinoma (Giannuzzo
et al., 2015), esophageal carcinoma (Santos et al., 2017),
papillary thyroid carcinoma (Kwon et al., 2014), renal cell
carcinoma (Liu et al., 2015), breast cancer (Tan et al.,
2015), prostate cancer (Ghalali et al., 2014), colorectal cancer
(Qian et al., 2017), and head and neck cancer (Bae et al.,
2017).
It is now consensus that under conditions of low-intensity
basal stimulation, P2X7 receptor has a potent pro-growth
activity, contributing to tumor progression (Di Virgilio, 2012).
P2X7 stimulation results in increased oxidative phosphorylation
and aerobic glycolysis, both events leading to an overall
enhancement in the total cellular ATP content (Adinolfi et al.,
2005; Amoroso et al., 2012) and consequent proliferative
advantage (Di Virgilio, 2016). P2X7 receptor activates several
intracellular growth promoting pathways, such as NFATc1, ERK,
PI3K/Akt, and HIF-1α (Jacques-Silva et al., 2004; Tafani et al.,
2011; Adinolfi et al., 2012; Amoroso et al., 2012, 2015). It also
triggers the release of vascular endothelial growth factor (VEGF)
(Hill et al., 2010; Adinolfi et al., 2012), tissue factor and matrix
metalloproteinases (Gu and Wiley, 2006), contributing to tumor
growth, angiogenesis, invasiveness, and metastasis spreading.
P2X7 receptor role in tumor metastasis is also supported by the
fact that its silencing leads to reduced expression of genes linked
to epithelial/mesenchymal transition such as Snail, E-cadherin,
Claudin-1, IL-8, and MMP-3 (Qiu et al., 2014).
Generally, the P2X7 receptor exhibits striking oncogene-
like features, being therefore a potential target in cancer
therapy. Many studies using P2X7 inhibitors and antagonist
have rendered promising results, reducing cancer growth or
spreading in preclinical animal models of colon cancer (Adinolfi
et al., 2012), breast cancer (Jelassi et al., 2011; Park et al.,
2016), ovarian cancer (Vázquez-Cuevas et al., 2014), pancreatic
ductal adenocarcinoma (Giannuzzo et al., 2016), neuroblastoma
(Amoroso et al., 2015), melanoma (Adinolfi et al., 2012, 2015),
glioma (Ryu et al., 2011), and mesothelioma (Amoroso et al.,
2016). The pharmacological molecules used to block P2X7
in those studies were administrated either intratumorally or
systemically and included oATP (Adinolfi et al., 2012; Hattori and
Gouaux, 2012), BBG (Vázquez-Cuevas et al., 2014), AZ10606120
(Adinolfi et al., 2012, 2015; Amoroso et al., 2015, 2016;
Giannuzzo et al., 2016), A740003 (Adinolfi et al., 2015; Amoroso
et al., 2015), A438079 (Jelassi et al., 2011), Antraquinone
emodin (Jelassi et al., 2013), novel 1-Piperidinylimidazole
based antagonists (Park et al., 2016), and P2X7 blocking
antibodies (Ren et al., 2010). Many pharmaceutical companies
are attempting to develop a clinical candidate targeting P2X7
receptor and various scaffolds have been disclosed (Park and
Kim, 2017). A recent clinical trial in phase I, which used an anti-
P2X7 antibody, provided significant data to support its use as a
safe and tolerable topical therapy for basal cell carcinoma (BCC)
(Gilbert et al., 2017). According to this study, 65% of patients
responded to the treatment, having a significant reduction in the
lesion area.
Considering P2X7 receptor role in promoting tumor
angiogenesis via increased HIF1α activity and VEGF secretion
(Adinolfi et al., 2012; Amoroso et al., 2012, 2015), it is tempting
to say that the use of antagonists of P2X7 in association with anti-
angiogenic drugs would surge synergistic effects in controlling
tumorigenesis. In fact, administration of the VEGF antagonist
Avastin strongly inhibits growth of P2X7-expressing tumors
in vivo (Adinolfi et al., 2012).
Although outcomes of pre-clinical and clinical studies are
exciting, novel P2X7-targeted strategy would only be feasible in
tumors that overexpress this receptor, as tumors with low or
no P2X7 expression showed slight response to P2X7 blocking
therapy in preclinical models (Adinolfi et al., 2012).
P2X7 Receptor Over-Activation in Tumor
Cells—Anti-tumoral Activities
Overstimulation of P2X7 receptor with high levels of exogenous
ATP in order to produce tumor cell death is a longstanding
observation and it was demonstrated in many types of cancer,
such as colon cancer (Bian et al., 2013; Mello et al., 2017a),
prostate cancer (Shabbir et al., 2008), cervical cancer (Wang
et al., 2004; Mello et al., 2014), endometrial cancer (Li et al.,
2006), melanoma (White et al., 2009; Feng et al., 2011; Bian
et al., 2013), squamous cell carcinomas (Deli and Csernoch,
2008), and glioma (Tamajusuku et al., 2010; Gehring et al., 2012,
2015), among others. However, despite its promising results in
preclinical models, clinical trials have failed to demonstrate a
potent anti-cancer effect for eATP administration in patients,
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with an improvement of the quality of life being the only
positive effect observed (Agteresch et al., 2003; Beijer et al., 2009,
2010).
This lack of effect in patients might be explained by the fact
that both tumor and other cells in the TME are resistant to the
high ATP concentrations usually present in this inflammatory
setting (Bianchi et al., 2014). The mechanism enrolled in such
refractoriness to ATP stimulation has not been completely
understood yet, but it appears to resultfrom P2X7 receptor
uncoupling from intracellular death pathways, at least in some
types of cancer (Raffaghello et al., 2006). Therefore, finding
strategies to enhance eATP-P2X7 signaling in the TME by
boosting P2X7 functional responses might be a better approach
to overcome cancer cell death escape in those cases where P2X7
receptor is less responsive.
We have recently demonstrated that hyperthermia is a
suitable strategy to augment ATP-elicited P2X7 functionality,
thereby maximizing tumor cell death (Mello et al., 2017a).
Hyperthermia alters plasma membrane fluidity facilitating P2X7
receptor pore opening and dilatation upon ATP stimulation
resulting in increased colon cancer cell death. Moreover, when
combined with cisplatin or mitomycin C, hyperthermia, and
eATP potentiate chemotherapy cytotoxicity, enhancing the
therapeutic efficacy of conventional cancer treatments. Likewise
hyperthermia, shock wave and photodynamic therapy alter
cells membrane permeability via ATP-P2X7 signaling, boosting
hydrophilic drugs intake, and cell death induction (Pacheco et al.,
2016; Qi et al., 2016). P2X7 receptor activation also modulates
radiotherapy-killing activity (Gehring et al., 2012, 2015).
According to Gering et al. eATP-P2X7 signaling acts
synergistically with radiotherapy potentiating glioma cell death
(Gehring et al., 2012, 2015). Moreover, silencing of P2X7
receptor in animal model of glioblastoma prevented response to
radiation, reinforcing that functional P2X7 receptor expression
is essential for an efficient radiotherapy response in gliomas
in vivo (Gehring et al., 2015). These studies combined bring
a different approach in relation to the use of eATP-P2X7
signaling intervention, specifically regarding its property to
increase plasma membrane permeability to boost the efficacy of
other anti-cancer modalities. Importantly, this strategy would
only be applicable to tumor cells expressing the P2X7(A)
splice variant, which is the well-characterized full-length
receptor capable of inducing pore formation and apoptosis
(Rassendren et al., 1997). So far, both functional and non-
functional splice variants have been described for the human
P2X7 receptor (Cheewatrakoolpong et al., 2005; Feng et al.,
2006a,b). The truncated P2X7(B) variant is a functional ion
channel with a dominant positive effect, however it lacks
the ability to form the large non-selective conductance pore
(Giuliani et al., 2014). Differently, the non-functional splice
variant P2X7(J) exerts a dominant negative effect (Feng et al.,
2006a,b). In these settings, tumor cells predominantly expressing
truncated/defective P2X7 receptor variant might fail to undergo
cell pore formation and death even with agonist stimulus
(Cheewatrakoolpong et al., 2005; Skarratt et al., 2005; Feng et al.,
2006a,b).
P2X7 Receptor in Tumor-Associated
Immune Cells
The TME is composed of different subsets of immune cells that
interact with tumor cells to enable tumor growth and progression
(de Visser et al., 2006; Hanahan and Weinberg, 2011). In this
inflammatory microenvironment, accumulated eATP activates
P2X7 receptor highly expressed in monocytes, macrophages,
DCs, lymphocytes, and myeloid-derived suppressor cells
(MDSCs), modulating the immune response against tumors
(Fernando et al., 1999; Gudipaty et al., 2003; Idzko et al.,
2014). In this scenario, P2X7 receptor activation on DCs is
crucial for the anti-immune response (Ghiringhelli et al.,
2009; Aymeric et al., 2010). Engagement of P2X7 receptor
triggers NLRP3 inflammasome activation and IL-1β release
with consequent stimulation of CD8+ and CD4+ mediated
anti-tumor responses. This signaling is particularly important
for the induction of immunogenic cell death after radiotherapy
and some chemotherapeutic agents, dictating the efficacy of
those treatments (Zitvogel et al., 2008; Ghiringhelli et al.,
2009; Aymeric et al., 2010). Moreover, two studies showed
that expression of P2X7 receptor by host immune cells
has a fundamental role in restraining tumor growth and
metastatic spreading (Adinolfi et al., 2015; Hofman et al.,
2015). Accordingly, tumors implanted in P2X7 KO mice
grow faster, lack inflammatory infiltrate—such as neutrophils,
lymphocytes, and macrophages—and metastasize more readily.
Furthermore, plasma and intratumoral levels of IL-1β and VEGF
were significantly lower in P2X7 KO compared to WT strains
(Adinolfi et al., 2015).
P2X7 receptor appears to hinder tumor growth by promoting
DC/tumor cell interaction, cytokine release, chemotaxis, and
infiltration of immune cells in the TME (Adinolfi et al.,
2015; Di Virgilio, 2016). It also stimulates the release of
immunosuppressive factors from MDSCs (Bianchi et al., 2014),
and modulates macrophages to the M2-immunosuppressive
phenotype, preventing tumor cell attack by natural killer and
T cells (Noy and Pollard, 2014; Bergamin et al., 2015). In this
complex scenario, the prevalence of one of those conflicting
inflammatory responses will dictate whether a tumor will
grow and metastasize or will be successfully hindered by the
immune system (Hanahan and Weinberg, 2011; Di Virgilio,
2016). In fact, the observation that systemic administration
of pharmacologic P2X7 receptor antagonist strongly inhibits
tumor growth in immune-competent mice (Adinolfi et al., 2012,
2015), suggests that blocking P2X7 receptor is more beneficial
for cancer regression. Evidence supporting this assumption
comes from the fact that, in tumors overexpressing P2X7
receptor, such as neuroblastoma, the anti-tumoral effect of
P2X7 antagonists is more pronounced in immune-competent
than in immune-compromised (nude/nude) mice, indicating
an additional contribution of the immune response against
tumor in the former case (Amoroso et al., 2015; Di Virgilio
and Adinolfi, 2017). This effect could be partially attributed to
blockade of P2X7 receptor expressed by suppressor immune cells
(i.e., MDSCs and M2-macrophages), restoring the anti-tumor
immune response.
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Therefore, targeting eATP/adenosine signaling is a promising
strategy to increase anti-tumor immunity in the TME and many
researchers have pointed the blockage of this signaling as the next
generation of cancer immunotherapy (Allard et al., 2017; Mello
et al., 2017b). Considering the diversity of cells, the complexity
of signaling, and the contradictory effect of P2X7 receptor in
the TME, the application of P2X7 receptor-blocking therapy to
restrain tumor growth and boost the anti-tumor immunity will
only be feasible after our complete understanding of its role in
the host-tumor interaction.
P2X7 RECEPTOR ACTIVATION IN
NEURODEGENERATIVE DISORDERS—A
DEMON VIA EXACERBATION OF
NEUROINFLAMMATION
In the brain, extracellular nucleotides, mainly ATP, act as
signaling molecules mediating neuron-neuron and neuron-glia
communication through activation of ionotropic (P2X) and
metabotropic (P2Y) purinergic receptors (Cisneros-Mejorado
et al., 2015). P2X7 receptor is widely distributed in the brain
(Yu et al., 2008) and it is abundantly expressed in microglia and
neurons, as well as in other glial cells such as oligodendrocytes
and astrocytes (Yu et al., 2008). P2X7 receptor plays a key
physiologic role on neural axonal growth and modulation of
neurotransmitter release from presynaptic terminals, where it is
prominently present (Sperlágh et al., 2002; Alloisio et al., 2008).
Its brief stimulation also induces non-cytotoxic glial activation.
However, in pathologic situations, even mild perturbations, ATP
can be released in large amounts from neurons and activated
glial cells, as well as from dying cells at the site of injury,
dramatically increasing eATP levels. Repeated and prolonged
activation of P2X7 receptor by high levels of eATP induces
formation of large non-selective membrane pores, in addition
to the typical Ca+2 influx and K+ eﬄux through non-selective
cationic channels, initiating a cascade of pro-inflammatory and
pro-apoptotic events that culminate in cell death. In addition,
P2X7 receptor pores may be a route of glutamate and ATP
eﬄux from glia and neurons, further fueling inflammation and
cytotoxicity (Di Virgilio et al., 2001; Liang and Schwiebert, 2005).
Neuroinflammation and gliosis are the most prominent
aspects in the pathophysiology of many neurodegenerative
diseases. Increasing evidence suggests that deregulated
expression and activation of P2X7 receptor is an underlying
key mechanism in the pathogenesis and progression of many
pathological states of central nervous system (CNS), particularly
due to its regulatory role in glial activation, integrity, and
survival. Activation of P2X7 receptor signaling in microglia
induces inflammasome formation, releases pro-inflammatory
cytokines (IL-1β, IL-18, and TNFα) and reactive oxygen species
such asROS, particularly superoxide (Parvathenani et al., 2003),
which induces activation of NFκB signaling, upregulation of
pro-inflammatory, and pro-apoptotic genes. This willresult in
death of surrounding cells, including neurons (Parvathenani
et al., 2003). ATP released from dying cells perpetuates the
inflammatory and degenerative cycle.
This cascade of events has been proposed as a common
pathological mechanism to many CNS diseases where an
initial perturbation, either mechanical, inflammatory, cytotoxic
or infectious, induces increased in eATP, triggering P2X7
receptor-dependent inflammatory and pro-apoptotic cascade. If
that holds true, such deleterious effects commonly present in
neurodegenerative diseases could potentially be manageable by
antagonists of P2X7 receptor, irrespective of the primary cause.
In fact, extensive body of work has demonstrated the
involvement of P2X7 receptor activation not only in microglia
but also in neurons, oligodendrocytes, and astrocytes, in the
development of multiple CNS disorders including Traumatic
Brain Injury, Parkinson’s disease, Alzheimer’s disease, ischemia,
epilepsy, Huntington’s disease, and Multiple Sclerosis. In the
next sections, we will focus on the role of P2X7 receptor in the
development and possible treatment of the neurodegenerative
disorders that most heavily affect patients worldwide: Alzheimer’s
disease (AD), Parkinson’s disease (PD), Huntington’s disease
(HD), and Multiple Sclerosis (MS). A detailed coverage of the
physiologic role of P2X7 receptor in the brain, as well as its role
in other CNS disorders, is available in recent reviews (Sperlágh
and Illes, 2014; Tewari and Seth, 2015; De Marchi et al., 2016).
Role of P2X7 Receptor in Alzheimer’s
Disease (AD)
According to the latest World Alzheimer Report from the
Alzheimer’s Disease (AD) International (an international
federation of Alzheimer associations around the world), 46
million people are living with AD or a related dementia, being
more than 10 million people only in the United States (“World
Alzheimer Report 2016 | Alzheimer’s Disease International”
2017). AD is a progressive form of dementia characterized by
increasing neuronal loss, mainly in cortex and hippocampus.
Neuropathological hallmarks of this disease are the presence
of neurofibrillary tangles, formed by the accumulation of
intracellular inclusions of hyperphosphorylated tau protein, and
the deposition of extracellular plaques of amyloid-β peptides
(Aβ) (Koffie et al., 2012; Pooler et al., 2014).
AD pathogenesis is complex and it has not been completely
understood yet. Aβ production and aggregation is still considered
to be at the origin of AD pathology, while Aβ-induced microglia
activation is believed to contribute to disease progression
through secretion of pro-inflammatory mediators and cytotoxic
agents (Hardy and Selkoe, 2002). Protein post-translation
modifications that promote inflammation, specifically the ureido
degenerative protein modification arginine citrullination and
lysine carbamylation, have been also associated with initiation
and progression of dementia and AD. Interestingly, Gallart-
Palau et al. (2017) have demonstrated presence of P2X7 receptor
modified by a dementia-specific citrulline residue in soluble
brain proteome of AD. However, the contribution of this post-
translational modification to P2X7 receptor’s activity remains to
be demonstrated. Upregulation of P2X7 receptor was observed
in the brain of AD patients, as well as in the hippocampus of
animal models of AD such as Tg2576 transgenic mice and rats
following intrahippocampal Aβ injection. In both cases, P2X7
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receptor brain expression was concentrated in areas of high
Aβ plaques density and co-localized with activated microglia,
identifying microglial P2X7 receptor as another player in the
pathogenesis of AD (Parvathenani et al., 2003; McLarnon et al.,
2006). More recently, in vitro autoradiography quantification
of brain slices incubated with a potent iodinated radiotracer
for P2X7 receptor, [123I]TZ6019, demonstrated higher binding
in brains from P301C tau transgenic mice, a tauopathy mouse
model of AD, compared to control (Jin et al., 2017). While the
cause of increased P2X7 receptor in AD is still unknown, studies
performed in human fetal microglia demonstrated a significant
two-fold upregulation in P2X7 receptor expression following in
vitro treatment with Aβ, suggesting a direct effect of this peptide
on P2X7 receptor expression (McLarnon et al., 2006).
Aβ also induces ATP release from microglia (Kim et al.,
2007). Released ATP, acting in an autocrine/paracrine manner,
further augments microglial activation, and likely contributes
to neuronal death (Rampe et al., 2004; Kim et al., 2007; Sanz
et al., 2009). Furthermore, due to its potent chemoattractant
properties, higher eATP levels contribute to the high density of
activated microglia surrounding Aβ plaques, a common finding
in the brain of AD patients. Most interestingly, the inability
of Aβ to activate P2X7 receptor deficient microglia suggests
a fundamental role for this receptor in microglial activation
induced by Aβ (Sanz et al., 2009). Supporting this assumption,
P2X7 receptor blockade with antagonists or P2X7 receptor
silencing prevented Aβ-induced pro-inflammatory signaling in
microglia (McLarnon et al., 2006; Ryu and McLarnon, 2008).
Silencing of P2X7 receptor also enhanced Aβ phagocytosis by
microglia, an important mechanism for Aβ clearance (Ni et al.,
2013).
A possible involvement for P2X7 receptor in modulating
amyloid precursor protein (APP) processing and Aβ peptides
production has also been proposed (Delarasse et al., 2011;
León-Otegui et al., 2011; Miras-Portugal et al., 2015). APP,
a transmembrane protein present in neurons and glia, can
be processed by α- and β-secretases, followed by sequential
cleavage by γ secretases to produce soluble APPα (sAPPα) and
amyloidβ (Aβ) fragments, respectively. While both pathways
of APP processing occur in the CNS, in a healthy brain, APP
is preferentially processed by α-secretases (non-amyloidogenic
process), precluding the formation of Aβ and resulting in sAPPα
accumulation, which has been shown to have neurotrophic
and neuroprotective properties. However, in AD brain, for
reasons still unknown, APP cleavage by β-secretases is more
pronounced, resulting in accumulation of Aβ peptides in senile
plaques (Murphy and LeVine, 2010). While the protective role of
activation of P2Y2 receptor in inducing the non-amyloidogenic
possessing of APP is well-established (Camden et al., 2005; Kong
et al., 2009), the contribution of P2X7 receptor is debatable.
Delarasse et al. (2011) performed studies using human and
mouse neuroblastoma cell lines that constitutively express APP
and a functional P2X7 receptor. They showed that these cells
release APP fragments when stimulated with both ATP and
high levels of BzATP. Interestingly, APP fragments were secreted
mostly as sAPPα while Aβ was undetectable, suggesting that
P2X7 receptor activation promotes APP cleavage predominantly
via α-secretase pathway. Moreover, this effect was abolished by
both P2X7 receptor siRNA and pre-treatment with P2X7 receptor
pharmacologic inhibitors, further validating the involvement of
P2X7 receptor signaling in promoting sAPPα release. These
results were also replicated in mouse primary astrocytes and
neural progenitor cells, as well as in human neuroblastoma
cells. In these cells, ATP increased sAPPα secretion in wild
type cells, but failed to do so in P2X7 receptor knockout cells.
This non-amyloidogenic APP cleavage induced by P2X7 receptor
activation was mediated by metalloproteases, via activation of an
ERK1/2, P38, and JNK signaling pathway, independently from
typical P2X7 receptor induced Ca+2 influx (Delarasse et al.,
2011). Such results suggest a protective effect of P2X7 receptor on
APP processing, contradicting the initial claims of a deleterious
role for P2X7 receptor activation in AD.
Follow up studies using the same mouse neuroblastoma
cells cited above, but applying a different methodology for
quantification of APP fragments, challenged those controversial
findings. Accordingly, two independent studies demonstrated
that BzATP-induced P2X7 receptor activation leads to decreased
α-secretase activity, which was prevented by P2X7 receptor
antagonists and P2X7 receptor siRNA (León-Otegui et al., 2011;
Miras-Portugal et al., 2015).
In agreement with these findings, studies performed in J20
mice, an in vivo model of AD in which Aβ senile plaques
develop spontaneously, demonstrated decreased Aβ plaques in
hippocampus of AD animals upon treatment with P2X7 receptor
antagonist BBG. This effect was attributed to a shift toward APP
metabolism by α-secretase via reduction of GSK3 activity (Diaz-
Hernandez et al., 2012), an enzyme known to phosphorylate
specific AAP domains, making it more suitable to be processed
into Aβ.
Altogether, those studies suggest that modulation of microglia
functions, as well as regulation of APP processing by P2X7
receptor antagonists, may be a promising therapeutic strategy in
the management of AD.
Role of P2X7 Receptor in Parkinson’s
Disease
Parkinson’s disease (PD) is a motor illness clinically characterized
by bradykinesia, rigidity, postural instability, and tremor at rest,
caused by progressive impairment of the striatal dopaminergic
system that evolves to loss of dopaminergic (DA) neurons in
the substantia nigra. While the mechanisms enrolled in PD
development are still not completely understood, a growing body
of evidence shows that chronic neuroinflammation and excessive
microglia activation strongly contribute to degeneration of DA
neurons within the substantia nigra and striatum of PD patients
(Durrenberger et al., 2012). Oligomerization and accumulation
of α-Synuclein (ASN) is also believed to be an important player
in the pathophysiology of PD. ASN mediates neurotoxicity
by inducing deregulation of dopaminergic and glutamatergic
neurotransmission and by activating microglia, with subsequent
production of pro-inflammatory molecules and reactive oxygen
species (Stefanis, 2012). Interestingly, ASN also binds and
activates P2X7 receptor in microglia and this interaction appears
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to be key to ASN-induced microglia ROS production, as it is
partially reduced in P2X7 receptor knockdown cells (Jiang et al.,
2015). Additionally, ASN stimulates P2X7 receptor transcription
(Jiang et al., 2015), which might explain, at least in part, the
P2X7 upregulation observed in brains of patients with PD
(Durrenberger et al., 2012).
In vivo indication of a possible involvement of P2X7 receptor
in the nigrostriatal degeneration first appeared in studies
using the 6-OHDA rat model of PD. In this animal model,
destruction of DA neurons is induced by unilateral intranigral
injection of a DA selective neurotoxin 6-hydroxydopamine (6-
OHDA). This leads to marked reduction of dopamine levels and
nigrostriatal lesions that are accompanied by microgliosis, as
typically found in autopsy of PD patients, culminating in the
development of motor symptoms, closely mimicking the human
disease. Administration of selective P2X7 receptor antagonists
ameliorated motor and memory deficit, and significantly
attenuated 6-OHDA-induced microgliosis (Marcellino et al.,
2010; Carmo et al., 2014; Ferrazoli et al., 2017; Kumar et al.,
2017), suggesting a pro-inflammatory role for P2X7 receptor
signaling via microglia activation in PD. In addition, P2X7
receptor antagonists significantly ameliorated 6-OHDA-induced
decrease in mitochondrial respiration, as well as increase in
oxidative stress and mitochondrial-linked apoptosis, adding
preservation of mitochondrial function and integrity to the
protective mechanisms of P2X7 receptor antagonists in PD
(Kumar et al., 2017).
While the evidence supporting the involvement of P2X7
receptor in PD neuroinflammation is strong, whether
direct activation of neuronal P2X7 receptor is responsible
for PD neurodegeneration has been subject of discussion.
Sensitivity of dopaminergic neurons to ATP- and 6-OHDA-
induced cytotoxicity via activation of P2X7 receptor has been
demonstrated in vitro (Jun et al., 2007; Carmo et al., 2014). Along
the same lines, in vitro studies performed in neuroblastoma
SH-SY5Y cells demonstrated that extracellular ASN directly
activates P2X7 receptor to induced ATP release, contributing
to neuronal toxicity in PD (Wilkaniec et al., 2017). However,
the association between activation of neuronal P2X7 receptor
and DA neuronal loss in vivo remains to be proven. Intranigral
injection of P2X7 receptor antagonist A438079 attenuated
depletion of striatal dopamine stores but it did not affect loss of
dopaminergic cells in the 6-OHDA PD model (Marcellino et al.,
2010). Similarly, genetic deletion and pharmacologic inhibition
of P2X7 receptor failed to promote neuroprotection in a mouse
model of PD induced by administration of the dopaminergic
neurotoxin MPTP (Hracskó et al., 2011).
On the other hand, BBG treatment significantly prevented
and even reversed loss of DA neurons in 6-OHDA-treated
animals, as evaluated by striatal content of tyrosine hydroxylase
(TH) (Carmo et al., 2014; Ferrazoli et al., 2017), the limiting
enzyme in the production of dopamine often used a surrogate for
number of DA neurons. Additional work done in an endotoxin-
induced model of PD confirmed the neuroprotective properties
of BBG. As in the rat 6-OHDA model, brain of LPS-treated
mice showed high levels of P2X7 receptor expressing activated
microglia in the substantia nigra that was, once again, reduced
by selective inhibition of the P2X7 receptor by BBG. Lower
microglia activation correlated with marked protection of DA
neurons from LPS-induced cytotoxicity, as assessed by number
of TH+ cells (Wang et al., 2017).
Collectively, those studies strongly support the hypothesis that
P2X7-induced microglia activation is involved in PD pathology.
However, they fail to demonstrate whether neuroprotection
conferred by P2X7 receptor antagonistic results solely from
inhibition of microgliosis or from direct effect on neuronal P2X7
receptor. Using the current immunohistochemistry tools, P2X7
receptor expression was showed to co-localize with nigrostriatal
glia in animal models of PD, not neurons. Brain analysis of the
recently generate, conditional humanized P2X7 receptor mice
confirmed the expression of P2X7 receptor in all major non-
neuronal lineages throughout the brain (astrocytes, microglia and
oligodendrocytes), as well as glutamatergic pyramidal neurons of
the hippocampus (Metzger et al., 2017), further questioning the
existence of these receptors in DA neurons.
Role of P2X7 Receptor in Multiple
Sclerosis (MS)
Multiple sclerosis (MS) is an immune-mediated, chronic
degenerative disease of the CNS, characterized by inflammatory
focal lesions in both white and gray matter, immune cell
infiltration, loss of oligodendrocytes, and axonal damage, leading
to demyelinization and neuronal death. Clinically, patients
present neurological deficit including sensory disturbances, lack
of motor coordination, and visual impairment (Lucchinetti et al.,
2011). An autoimmune inflammatory reaction to myelin is
believed to be the triggering event in the pathogenesis of MS,
with genetic and environmental factors strongly contributing
to disease susceptibility (Kidd, 2001; Stys, 2010). Due to the
highly inflammatory nature of MS, a link between P2X7 receptor
activation and MS development has been proposed.
While MS is seen most traditionally as a “white matter”
disease, with loss of oligodendrocytes and damage to myelin
being the core of its pathology, the involvement of other cell
types such as neurons and glia on the development of this disease
has also been recognized. In fact, increased in P2X7 receptor
expression has been reported in oligodendrocytes, neurons and
glia of MS patients.
Early post mortem studies have revealed high P2X7 expression
in astrocytes and activated microglia in the brain and spinal
cord of MS patients (Narcisse et al., 2005; Yiangou et al.,
2006). Deregulated P2X7 expression seems to precede the
symptomatology of the disease, as increased P2X7 levels are
present in normal appearing optic nerve samples of MS patients
(Matute et al., 2007), suggesting that deregulated P2X7 signaling
might be a risk factor associated with early lesion development
of MS.
A better understanding of the kinetics of P2X7 receptor
expression in MS is provided by studies performed with rat
models of experimental autoimmune encephalomyelitis (EAE).
EAE is the most common rodent model used to study the
molecular mechanisms responsible for the development of
inflammation and progressive demyelination characteristics
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of MS (Tsunoda and Fujinami, 1996). In this model, EAE
symptoms start 7 days following immunization. Full-
blown symptomatology, characterized by paralysis of tail,
hind limbs, and loss of reflexes, develops at 10 days. The
disease spontaneously resolves by 15 days following initial
immunization.
Temporal analysis of P2X7 receptor expression and its
relation to disease progression showed biphasic increase on P2X7
receptor expression in the brain of EAE rats, which was most
evident in the frontal motor and somatosensory cortical areas,
with higher intensity in the deep cortical layers. Upregulation of
P2X7 receptor occurred in astroglia cells at very early stage, when
animals were still asymptomatic (Grygorowicz et al., 2010). P2X7
receptor upregulation in neurons and oligodentrocytes occurred
later, corresponding to a moment of maximal neurological
symptoms, and then decreases to base line levels during the
recovery phase (Matute et al., 2007).
Such kinetics indicates that P2X7 receptor-induced cytokine
release by glia likely contributes to the inflammatory milieu
established very early in the disease development. Higher
expression of P2X7 receptor in neurons and olygodendrocytes
in the acute phase of the disease, corresponding to a peak in
inflammatory cytokine levels and cells death, further intensifies
the cytotoxic effects of P2X7 receptor signaling in these cells,
contributing to progressive inflammation and degeneration in
EAE. Interestingly, total P2X7 receptor levels remained high in
the brain of EAE rats even 20 days after immunization and
it correlates to increased levels of glial fibrillary acidic protein
(GAFP), a marker of astrocyte activation, suggesting a role for
P2X7 receptor activation in the sustained astrocytosis that is
observed in the advanced stages of the disease, in both EAE and
MS, despite clinical recovery (Holley et al., 2003; Grygorowicz
et al., 2011). A study performed in brain samples from MS
patients has shown up-regulation of P2X7 receptor on astrocytes
in the parenchyma of frontal cortex from secondary progressive
MS patients, validating the animal findings (Amadio et al., 2017).
Increased P2X7 receptor expression correlates with higher
P2X7 receptor signaling in MS. Supporting this assumption,
in vitro and in vivo animal studies have shown that enhanced ATP
signaling via P2X7 receptor activation leads to oligodendrocytes
excitotoxicity and death, resulting in tissue damage that
highly resembles MS lesions. Moreover, administration of
P2X7 receptor antagonist to EAE rats significantly decreases
astrogliosis, reduces demyelination, and improves neurological
symptoms (Matute et al., 2007; Grygorowicz et al., 2016).
These findings reinforce eATP-P2X7 signaling as a key factor
contributing to MS pathology and the potential use of
P2X7 pharmacological blockers to prevent or ameliorate MS
symptoms.
Interestingly, temporal analysis of P2X7 receptor expression
and activity in myeloid cells in MS patients demonstrated
that P2X7 receptor is present but inhibited on peripheral
monocytes during the acute phase, while totally absent from
microglia/macrophages during the secondary progressive phase.
This possibly granted these cells increased survival and further
contributed to neuroinflammation in both phases of the disease
(Amadio et al., 2017).
Several independent European and Australasian case-control
cohort discovery studies have identified a significant association
of a rare, loss-of-function, minor allele frequency P2X7 receptor
single nucleotide gene polymorphism (SNP), rs28360457,
coding for Arg307Gln with protection against MS. The same
European cohort also demonstrated a significant association
of gain-of-function haplotype in P2X7 receptor with increased
risk of MS. Functional studies using monocytes of normal
subjects heterozygous carriers of rs28360457 revealed dominant
negative effects on pore formation and downstream pro-
inflammatory effects, while monocytes harboring the gain-of-
function haplotype showed receptor activity two-fold higher
than controls (Gu et al., 2015). In addition, a Spanish case-
control association study found increased frequency of a gain-of-
function SNP, rs17525809, in MS patients compared to control
(Oyanguren-Desez et al., 2011). Altogether, the mentioned
studies strengthen the hypothesis that P2X7 receptor’s gene
variants may play a major role in the pathogenesis of MS.
Such data also reinforce P2X7 receptor increased expression and
functionality as an important feature in MS disease.
Role of P2X7 Receptor in Huntington’s
Disease (HD)
Huntington’s disease is an inherited neurodegenerative disorder
caused by a CAG triplet-repeat expansion coding for a
polyglutamine (polyQ) sequence in the N-terminal region of the
huntingtin (HTT) protein, leading to progressive degeneration of
nerve cells in the brain, predominantly in the cortex and striatum.
Clinically, patients present progressive cognitive decline, motor,
and psychological dysfunction. The molecular mechanisms
behind HTT toxicity are still under investigation, but recent
studies have suggested a possible role for ATP and P2X7 receptor
activation in the pathophysiology of HD.
Increased mRNA and protein levels of P2X7 receptor were
described in the brain of two distinct genetic mouse models
of HD (Tet/HD94 and R6/1) as compared to WT mice
(Díaz-Hernández et al., 2009). In both animal models, P2X7
receptor protein levels were increased at the onset of the motor
impairment, and occurred in axonal processes of cortical neurons
projecting to the striatum, particularly at the level of synaptic
terminals. Moreover, aging related decline of P2X7 receptor levels
in striatum that normally occurs in WT mice was less prominent
or totally absent in HD mice. Increased synaptic P2X7 receptor
expression correlated with modified calcium flux in response
to BzATP in synaptosomes isolated from HD mice vs. control
WT, suggesting altered P2X7 function in HD synaptic terminal.
This may explain the increased sensitivity to BzATP-induced
apoptosis in mutant-HTT-expressing primary cortical neurons
in culture, which was prevented by BBG (Díaz-Hernández et al.,
2009). However, how mutant HTT expression modulates P2X7
receptor levels remains unknown.
Supporting evidence for the involvement of P2X7 receptor
in HD onset and development comes from the fact that BBG
treatment prevented body weight loss and deterioration of
motor coordination of R6/1 mouse model of HD as compared
to vehicle-treated HD mice.This protective effect might be
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correlated with lower caspase-3 activation in neurons (Díaz-
Hernández et al., 2009). Interestingly, P2X7 receptor inhibition
was only beneficial when BBG was administered at the age that
immediately preceded symptom onset, and had no significant
effect when used at earlier ages. This data suggests that a
therapy using P2X7 antagonists might be successful only when
administered at more advanced stages of the disease, when P2X7
receptor expression is already altered. An important note, despite
several reports of the anti-inflammatory effects of P2X7 receptor
antagonists inmicroglia, BBG did not affect reactive gliosis in this
HD model (Díaz-Hernández et al., 2009).
Collectively, all those studies support the hypothesis
that upregulated expression and function of P2X7 receptor
contribute to the pathogenesis of several neuroinflammatory
and neurodegenerative diseases, and identify P2X7 receptor as a
potential druggable therapeutic target.
BRAIN PERMEABLE P2X7 RECEPTOR
PHARMACOLOGICAL INHIBITORS
The development of CNS-permeable P2X7 receptor antagonists
has been at the center of intense efforts in the pharmaceutical
industry in the last 15 years, a task that has been quite challenging
due to poor molecular stability and pharmacokinetic properties.
Availability of P2X7 ligands and inhibitors suitable for in vivo
studies is limited. Despite that, several in vivo studies have
shown benefits of P2X7 receptor antagonists in animal models
of neurodenegerative diseases.
BBG is the P2X7 antagonist most used in animal models
of brain disease due to its ability to efficiently cross the
blood-brain-barrier (BBB) and infiltrate the brain parenchyma.
Intraperitoneal administration of 54.5 mg/kg of BBG results in
200 nM of this compound in the brain in mice, a concentration
that is within the range of IC50 of BBG to antagonize P2X7
receptor (10–200 nM) and bellow the DL50 by one order
magnitude. BBG efficiency in improving disease outcomes has
been repeatedly reported in mice models of HD, AD, PD,
and epilepsy. However, it is less efficient at antagonizing P2X7
receptor in human than rodents (Jiang et al., 2000). In addition
to BBG, the P2X7 receptor blocker A438079 can also cross
the BBB, but its use in animal studies has been restricted
due to its short half-life (1.02 h) and limited bioavailability
(19%) (Nelson et al., 2006). Such pharmacokinetic properties
make A438079 inappropriate for chronic applications or clinical
purposes. (Díaz-Hernández et al., 2009; Marcellino et al., 2010).
While several classes of specific P2X7 receptor inhibitors
have been developed lately, only few of them can efficiently
cross the BBB. Despite this progress, finding a potent, selective
and CNS penetrable P2X7 receptor inhibitor with acceptable
pharmacokinetics (PK), particularly clearance, is still challenging
academic researchers and pharmaceutical companies.
In 2010, Pfizer developed a potent P2X7 receptor
antagonist (IC50 27 nM), 2-chloro-N-((4,4-difluoro-
1-hydroxycyclohexyl)methyl)-5-(5-fluoropyrimidin-2-
yl)benzamide, which is an improved version of 2-
chlorobenzamide template previously disclosed by AstraZeneca
(Guile et al., 2009). This compound showed excellent CNS
penetrability, with a brain/plasma ratio of 1.3, in addition
to better PK properties when tested in rats: clearance of 3.3
mL/min/kg, 4.6 h half-life and high oral bioavailability of 84%
(Chen et al., 2010).
Three years later, Janssen Research and Development released
preclinical studies using two newly developed P2X7 receptor
antagonists (Letavic et al., 2013). Both compounds demonstrated
high potency across different species and reached high levels
in the animal’s brain. They were also able to successfully
reduce signs of neuroinflammation, epilepsy, and seizure, as
well as improve behavior in animal models of schizophrenia,
hyperactivity, and social stress. However, their compounds had
poor PK properties, making them unsuited to further clinical
applications (Letavic et al., 2017).
Researchers from The University of Sydney and University
of South Australia have recently discovered a new adamantly-
cyanoguanidine hybrid compound (O’Brien-Brown et al., 2017).
This new hybrid molecule combined two promising classes of
P2X7 receptor antagonist as to retain desirable characteristics of
each category, i.e., good pharmacokinetic properties of truncated
cyanoguanidines scaffold reported by Abbott Laboratories and
high potency and selectivity of the adamantyl amide moiety
disclosed by AstraZeneca. Using structure-activity studies (SAR)
and in vitro measurement of P2X7 receptor activity, they
identified two promising P2X7 receptor antagonist candidates
(IC50 < 50 nM). Unfortunately, the compound identified as
having the best druggability, a 3-pyridyl analog, showed poor PK
in mice, with a fast clearance (117 mL/min.kg) and extremely
short half-life (0.22 h), making it unsuitable for human clinical
studies (O’Brien-Brown et al., 2017). While brain levels of
the compound were not measured, indirect evidence for CNS
penetrability and inhibition of P2X7 receptor in vivo was
provided by improvement in scape-oriented behavior in forced
swimming test (FST), a test designed to evaluate depressive
behavior in mice, following administration of the compound.
This observation agrees with previous FST studies performed in
P2X7 KO mice (Boucher et al., 2011).
Janssen Research & Development has also been working
on a series of modification substitutions of the 4-methyl-6,7-
dihydro-4H-triazolo[4,5-c] pyridine core in order to develop
a P2X7 receptor antagonist suitable for clinical use (Letavic
et al., 2017). In vivo studies in rats and dogs using the most
promising candidate among those modified molecules have
shown efficient inhibition of IL-1β release in the brain, with no
significant clinical or metabolic side-effects even at the highest
administered doses. Based on such performance on PK, efficacy
and safety test in animals, Jansen has moved to its first steps
in clinical development of their compound and safety tests in
healthy volunteers are on their way (Letavic et al., 2017). Their
newly developed compound demonstrated very low clearance
across several species, including non-human primates, and high
bioavailability, which predicted human clearance of 0.6 mL/kg
and half-life of 29 h.
Despite all advances in the development of CNS penetrable
P2X7 receptor antagonist and promising preclinical evidence, no
clinical trial using P2X7 antagonists for treatment CNS disorders
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FIGURE 2 | Schematic illustration showing P2X7 receptor deleterious (demon) effects in inflammatory and neurodegenerative disease. (A) ATP can be released from
injured immune and non-immune cells activating P2X7 receptor. As a consequence, P2X7 receptor activation induces large-scale ATP release—chiefly via pannexin
hemichannels—acting as a start point to inflammation. In this scenario, P2X7 activation contributes to the pathogenesis of several inflammatory diseases by activating
intracellular signaling pathways and stimulating the production of pro-inflammatory mediators (i.e., ROS, NO, chemokines, and cytokines). In addition, P2X7 receptor
induces T cell activation, decreases the suppressive activity and viability of Treg cells and favors the polarization of T cells into Th17 cells promoting inflammation and
cell death. (B) Likewise, microglial P2X7 receptor activation in neurodegenerative diseases induces inflammasome activation and release of pro-inflammatory
cytokines and ROS, leading to the activation of NF-κB signaling, upregulation of pro-inflammatory and pro-apoptotic genes, and death of surrounding cells, including
neurons. ATP released from dying cells perpetuates the inflammatory and degenerative cycle, at least in part, via P2X7 receptor. (C) P2X7 receptor activation has
been linked to conflicting effects on carcinogenesis, being able to exert either pro-tumoral (demon) or anti-tumoral (angel) effects depending on its level of activation
and cell type studied. Left: Pro-tumoral effects are associated with P2X7 receptor basal stimulation in tumor cells as well as its activation in immunussupresive cells
such as MDSCs and M2-macrophages. Right: On the other hand, anti-tumoral effects can be trigger by P2X7 overstimulation with high levels of exogenous ATP in
tumor cells, resulting in membrane pore formation and cell death through apoptosis. In this inflammatory context, eATP accumulation also activates P2X7 receptor
highly expressed in DCs, T effectors, NK, and macrophages, boosting the immune response against tumors.
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have been conducted to date. GlaxoSmithKline completed a
phase I clinical trial to evaluate safety and pharmacodynamics of
its pyroglutamate-based P2X7 inhibitor GSK1482160, intended
for the treatment of pain and inflammation. Interestingly, this
compound has good CNS penetration (B/P ∼0.5). However,
while no major safety issues were observed, conclusions from
phase I clinical trial led to the discontinuation of the study (Ali
et al., 2013). In fact, only three other P2X7 receptor antagonists
have been used in clinical trials. In 2009, Pfizer completed a Phase
2a, Randomized, Double-Blind, Placebo-Controlled clinical trial
to evaluate the compound CE-224,535 for the treatment of
signs and symptoms of rheumatoid arthritis (Stock et al., 2012).
Few years later, AstraZeneca performed a phase IIa study and
subsequently in a phase IIb clinical trial to assess the effects
of AZD9056 on the symptoms of rheumatoid arthritis as well.
Unfortunately, despite encouraging results regarding safety, all
trial failed to demonstrate efficacy of the compounds in the
treatment of RA (Keystone et al., 2012).
CONCLUSION
P2X7 is a multifaceted receptor involved in several physiological
and pathological conditions in different body systems by
modulating cellular responses in immune and non-immune cells.
In infectious inflammatory disease and cancer, P2X7 receptor
can have different and contrasting effects, being an angel or a
demon depending on its level of activation, cell studied, and type
of pathogen.
Overall, ATP-P2X7 receptor signaling boosts the immune
system in the context of pathogen infections, activates
microbicidal mechanisms, and induces the production
of inflammatory mediators in phagocytic cells, as well
as modulates adaptive immune responses. Nevertheless,
P2X7 receptor activation can generate both protective and
deleterious responses depending on the type of pathogen,
virulence, and severity of infection. The activation of this
ATP-gated ion channel shows deleterious effects during
infections by hypervirulent pathogens, inducing severe
inflammation and necrotic cell death, release of large
amounts of ATP, which results in sustained P2X7 receptor
activation, leading to a self-sustained pro-inflammatory cycle
(Figure 1).
Likewise, increased expression and prolonged activation
of P2X7 receptor contribute to the pathogenesis of several
inflammatory and neurodegenerative diseases. In the context
of these pathologies, P2X7 receptor acts as a start point to
initiate inflammation and promotes disease progression by
regulating T cell adaptive immune responses. Initially, it can
be activated by ATP released from both injured immune and
non-immune cells. As a consequence, P2X7 induces large-scale
ATP release, boosting inflammation and purinergic signaling.
Upon activation, P2X7 triggers intracellular signaling pathways,
stimulates the production of pro-inflammatory mediators (i.e.,
ROS, NO, chemokines, and cytokines), and, consequently,
promotes the migration of immune cells to the inflammatory
site. In addition, P2X7 receptor induces T cell activation,
decreases the suppressive activity and viability of Treg cells and
favors the polarization of T cells into Th17 cells, promoting
inflammation and cell death (Figure 2). Therefore, P2X7 receptor
pharmacological inhibition or genetic deletion in different
inflammatory models completely abrogates or significantly
attenuates inflammation and disease progression.
Finally, the outcomes of studies—aimed at understanding
P2X7 pharmacology and using P2X7 receptor agonists,
antagonists, and P2X7 KO mice—should be carefully analyzed
and discussed in order to accurately bring up the biology and
relevance of this receptor in the context of inflammatory and
infectious diseases. In addition, peculiarities of each parasite
infection and inflammatory disease should be considered when
developing pharmacological treatments targeting P2X7 receptor.
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